Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Citric acid cycle wikipedia , lookup
Metalloprotein wikipedia , lookup
Lipid signaling wikipedia , lookup
Fatty acid synthesis wikipedia , lookup
Basal metabolic rate wikipedia , lookup
Evolution of metal ions in biological systems wikipedia , lookup
Biochemistry wikipedia , lookup
Am J Physiol Heart Circ Physiol 291: H1489 –H1506, 2006. First published June 2, 2006; doi:10.1152/ajpheart.00278.2006. Invited Review Role of changes in cardiac metabolism in development of diabetic cardiomyopathy Ding An and Brian Rodrigues Division of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada heart disease; diabetes; insulin resistance; lipoprotein lipase; fatty acid transporters; PPARs; lipotoxicity; mitochondria dysfunction HEART DISEASE is a leading cause of death in diabetic patients (226, 253), with coronary vessel disease and atherosclerosis being primary reasons for the increased incidence of cardiovascular dysfunction (151, 225, 253). However, a predisposition to heart failure might also reflect the effects of underlying abnormalities in diastolic function that can be detected in asymptomatic patients with diabetes alone (24, 61, 74). These observations suggest a specific impairment of heart muscle (termed diabetic cardiomyopathy). Rodent models of chronic diabetes demonstrate abnormalities in diastolic left ventricular function, with or without systolic left ventricular dysfunction (73, 205, 219). Because diastolic dysfunction is also seen in patients with both Type 1 and Type 2 diabetes, it can be proposed that the diabetic state can directly induce abnormalities in cardiac tissue independent of vascular defects. Several etiological factors have been put forward to explain the development of diabetic cardiomyopathy, including an increased stiffness of the left ventricular wall associated with accumulation of connective tissue and insoluble collagen (9, 204, 212) and abnormalities of various proteins that regulate ion flux, specifically intracellular calcium (90, 235). More recently, the view that diabetic cardiomyopathy could also occur as a consequence of metabolic alterations has been put forward (146, 147, 149). Address for reprint requests and other correspondence: B. Rodrigues, Div. of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, The Univ. of British Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3 (e-mail: [email protected]). http://www.ajpheart.org Because uninterrupted contraction is a unique feature of the heart, cardiac muscle has a high demand for provision of energy. Under normal physiological conditions, hearts can utilize multiple substrates, including fatty acids (FA), carbohydrate, amino acids, and ketones (15). Among these substrates, carbohydrates and FA are the major sources from which the heart derives most of its energy. In a normal heart, 70% of ATP generation is through FA oxidation, whereas glucose and lactate account for ⬃30% of energy provided to the cardiac muscle (86, 173, 210). It should be noted that the heart can rapidly switch its substrate selection to accommodate different physiological and pathphysiological conditions involving altered extracellular hormones, substrate availability, and workload (energy demand) (11, 130, 204, 217, 227). Acutely or chronically, this regulation occurs through various mechanisms. Although substrate switching is essential to ensure continuous ATP generation to maintain heart function, it has also been associated with deleterious consequences (17, 267). In Type 1 and Type 2 diabetes mellitus, glucose uptake, glycolysis, and pyruvate oxidation are impaired. Additionally, lack of insulin function augments lipolysis and release of FA from adipose tissue. Under these conditions, the heart rapidly adapts to using FA exclusively for ATP generation. Chronically, this maladaptation is believed to play a key role in the development of cardiomyopathy. Hence, it is essential to identify and understand the mechanisms that control substrate utilization in the diabetic heart. This review discusses the acute and chronic cellular changes that modify cardiac metabolism and elucidate their roles in the development of cardiomyopathy. 0363-6135/06 $8.00 Copyright © 2006 the American Physiological Society H1489 Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 An, Ding, and Brian Rodrigues. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 291: H1489 – H1506, 2006. First published June 2, 2006; doi:10.1152/ajpheart.00278.2006.—In patients with diabetes, an increased risk of symptomatic heart failure usually develops in the presence of hypertension or ischemic heart disease. However, a predisposition to heart failure might also reflect the effects of underlying abnormalities in diastolic function that can occur in asymptomatic patients with diabetes alone (termed diabetic cardiomyopathy). Evidence of cardiomyopathy has also been demonstrated in animal models of both Type 1 (streptozotocin-induced diabetes) and Type 2 diabetes (Zucker diabetic fatty rats and ob/ob or db/db mice). During insulin resistance or diabetes, the heart rapidly modifies its energy metabolism, resulting in augmented fatty acid and decreased glucose consumption. Accumulating evidence suggests that this alteration of cardiac metabolism plays an important role in the development of cardiomyopathy. Hence, a better understanding of this dysregulation in cardiac substrate utilization during insulin resistance and diabetes could provide information as to potential targets for the treatment of cardiomyopathy. This review is focused on evaluating the acute and chronic regulation and dysregulation of cardiac metabolism in normal and insulinresistant/diabetic hearts and how these changes could contribute toward the development of cardiomyopathy. Invited Review H1490 ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES DIABETIC CARDIOMYOPATHY AJP-Heart Circ Physiol • VOL CARDIAC METABOLISM Glucose Uptake and Oxidation Under normal physiological conditions, glucose is one of the major carbohydrates utilized by the heart. Glucose metabolism is regulated through multiple steps, including uptake, glycolysis, and pyruvate decarboxylation (Fig. 1). Cardiac glucose uptake is dependent on the transmembrane glucose gradient and the content of sarcolemmal glucose transporters (GLUT1 and GLUT4) (132, 154, 189). GLUT1 has a more pronounced sarcolemmal localization and represents basal cardiac uptake. When compared with GLUT1, GLUT4 is the dominant transporter in the adult heart, and under basal conditions, a majority of this transporter is located in an intracellular pool (154). Its translocation from an intracellular compartment to the sarcolemmal membrane requires insulin (154). Other than recruiting GLUT to the sarcolemmal membrane, insulin also influences glucose transport through its regulation of GLUT gene expression (137, 183). It should be noted that GLUT-mediated glucose uptake could also be stimulated through insulin-independent mechanisms. For example, recent studies have demonstrated that AMP-activated protein kinase (AMPK) also promotes GLUT4 redistribution to the sarcolemmal membrane (143, 261). Once inside the cardiomyocyte, glucose is broken down through glycolysis, a sequence of reactions that convert glucose into pyruvate. Phosphofructokinase-1 (PFK1), the enzyme that catalyzes the generation of fructose 1,6-bisphosphate from fructose 6-phosphate, is a rate-limiting enzyme controlling glycolysis (57, 202). PFK-1 is inhibited by low pH, high 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 The central basis for diabetic heart failure is coronary disease associated with atherosclerosis (151, 225, 253). Because diabetes is often accompanied by hypertension and/or ischemic heart disease, which often causes diastolic dysfunction, it is difficult to attribute heart failure in these patients to diabetes alone (23). On the other hand, Type 1 or Type 2 diabetic patients have also been diagnosed with reduced or low-normal diastolic function and left ventricular hypertrophy in the absence of coronary heart disease or hypertension, identified as cardiomyopathy (24, 81, 192, 195, 200, 231). These abnormalities in asymptomatic diabetic patients potentially might predispose them to symptomatic heart failure when they develop hypertension or ischemic heart disease, particularly after myocardial infarction. In animal models of Type 1 diabetes, either streptozotocin (STZ)-induced rats or genetic nonobese diabetic mice, systolic and diastolic dysfunction have been demonstrated using in vivo or in vitro measurements (177, 185, 232, 239). For example, systolic and diastolic dysfunction have been detected by using echocardiography in STZ diabetic animals (123, 177). With the use of in vivo catheterization of these animals, elevated left ventricular end-diastolic pressure and reduced left ventricular systolic pressure with diminished increase or decrease pressure over time (⫾dP/dt) were observed (124). Reduced peak left ventricular pressure and ⫾dP/dt were confirmed in ex vivo perfused STZ hearts (239). Recently, evidence of cardiomyopathy has also been reported in animal models of insulin resistance and Type 2 diabetes (ZDF rats and ob/ob or db/db mice) (5, 21, 30, 266). In db/db mice, systolic and diastolic dysfunction were detected by echocardiography (218). With the use of ex vivo perfused hearts from db/db mice, augmented left ventricular end-diastolic pressure and reduced cardiac output and cardiac power have also been observed (21). Given that rodents are resistant to atherosclerosis, these models provided strong evidence for the occurrence of diabetic cardiomyopathy. However, in another study, no evidence of impairment in cardiac function was detected using in ex vivo Langendorff perfusions of hearts from insulin resistant and obese Zucker rats (224) and Type 2 diabetic Zucker diabetic fatty (ZDF) rats (250). It is likely that such inconsistencies arose due to the rodent models used and the methods employed for evaluating heart function in the different studies. It should be acknowledged that the features of cardiomyopathy between human diabetic patients and rodent diabetic models might be different. The development of diabetic cardiomyopathy is influenced by the severity and duration of alterations in plasma parameters such as insulin, leptin, glucose, and lipids. Given the discrepancy in changes in these hormones and substrates between human diabetic patients and rodent models of Type 1 and Type 2 diabetes, the etiology and severity of diabetic cardiomyopathy may vary (196). For example, STZ-induced diabetes exhibit severe hypoinsulinemia, whereas ob/ob mice show leptin deficiency, which are rare in human diabetes. Additionally, it has been suggested that STZ can directly impair the cardiac contractile function of isolated ventricular myocytes (256). Finally, although db/db mice and Zucker and ZDF rats exhibit hyperinsulinemia, hyperleptinemia, and hyperglycemia, the severity of these alterations vary between animal models and patients with diabetes (196). Taken together, experimental data obtained using animals models of diabetes should be used with caution when extrapolating to the human condition. Cardiomyopathy is a complicated disorder, and several factors have been associated with its development. These include increased stiffness of the left ventricular wall associated with accumulation of connective tissue and insoluble collagen (204, 212), depressed autonomic function (73), impaired endothelium function and sensitivity to various ligands (e.g., -agonists) (23), and abnormalities of various proteins that regulate ion flux, specifically intracellular calcium (90, 235). More recently, there is a generalized view that diabetic cardiomyopathy also occurs as a consequence of altered fuel metabolism. During insulin resistance or diabetes, glucose utilization is compromised. This alteration, together with increased FA supply, switches cardiac energy generation to utilization of FA. High FA uptake and metabolism not only augment accumulation of FA intermediates and triglycerides but also increase oxygen demand and generation of reactive oxygen species (ROS), leading to cardiac damage. Interestingly, increasing FA uptake through overexpression of cardiac human lipoprotein lipase (LPL) (260) or FA transport protein (47), or augmenting FA oxidation through overexpression of cardiac peroxisome proliferator-activated receptor (PPAR)-␣ (79) or long-chain acyl CoA synthase (48), results in a cardiac phenotype resembling diabetic cardiomyopathy. Conversely, normalizing cardiac metabolism in diabetic animals reverses the development of cardiomyopathy (21, 272). Taken together, these studies strongly support the role of altered metabolism in the development of diabetic cardiomyopathy. Invited Review ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES H1491 (107, 258), which is inhibited by pyruvate and stimulated by high mitochondrial acetyl-CoA-to-CoA and NADH-toNAD(⫹) ratios (29, 104). Acetyl-CoA then enters the tricarboxylic acid cycle and is eventually broken down to H2O and CO2 for ATP generation. Oxidation of one glucose provides 30 ATP with 6 oxygen consumed, which combined with 2 glycolytic ATPs produces a phosphate-to-oxygen ratio of 2.58 ATP/ oxygen atom. Although glucose is the focus in this review, other carbohydrates like lactate also make an important contribution toward cardiac energy generation (39). In fact, as greater lactate compared with glucose utilization is observed in the isolated working heart (119, 127, 148), the inclusion of lactate in the perfusion buffer is recommended in future studies. Fig. 1. Glucose utilization in the cardiomyocyte. Glucose uptake into cardiomyocyte occurs through GLUT1 and GLUT4 transporters. Once inside, glucose is broken down through glycolysis, a sequence of reactions that convert glucose into pyruvate. Phosphofructokinase-1 (PFK1), the enzyme that catalyze the generation of fructose 1,6-bisphosphate from fructose 6-phosphate, is a rate-limiting enzyme controlling glycolysis. PFK1 is activated by 2,6bisphosphate, which is formed from fructose 6-phosphate catalyzed by PFK-2. After glycolysis, the pyruvate generated is transported into mitochondria and decarboxylated to acetyl-CoA through pyruvate dehydrogenase (PDH), a multienzyme complex. PDH is phosphorylated and inactivated by pyruvate dehydrogenase kinase (PDK). Acetyl-CoA then enters tricarboxylic acid cycle (citric acid cycle) and is eventually broken down to H2O and CO2 for ATP generation. intracellular citrate, or ATP and is activated by ADP, AMP, phosphate, and fructose 2,6-bisphosphate (57, 202, 228). Fructose 2,6-bisphosphate is formed from fructose 6-phosphate catalyzed by PFK-2 (110). Given that PFK-2 is phosphorylated and activated by hormones, such as insulin (25, 58) and glucagon (228) or kinases such as AMPK (109, 161), stimulation of PFK-2 through these mechanism increases fructose 2,6-bisphosphate generation, activates PFK-1, and subsequently promotes glycolysis. In an aerobic heart, glycolysis contributes ⬍10% of total ATP generated, with no oxygen consumption. After glycolysis, the pyruvate generated has three destinations: carboxylation to oxaloacetate or malate, reduction to lactate, and most importantly, decarboxylation to acetyl-CoA. To be oxidized, pyruvate is transported into the mitochondria and decarboxylated to acetyl-CoA through pyruvate dehydrogenase (PDH), a multienzyme complex. PDH is phosphorylated and inactivated by pyruvate dehydrogenase kinase (PDK) AJP-Heart Circ Physiol • VOL When compared with glucose, FA is the preferred substrate and accounts for ⬃70% of ATP generated in an aerobic heart. FA metabolism includes multiple steps and can be regulated by both acute and chronic mechanisms, with or without modulation of gene expression (Fig. 2). Lipoprotein lipase. Because the heart has limited capacity to synthesize and store FA, it relies on continuous exogenous supply. FA supplied to the heart from the circulation is from two sources: albumin-bound FA and triglyceride (TG)-rich lipoproteins. It should be noted that the molar concentration of FA in lipoprotein-TG is ⬃10-fold larger than FA bound to albumin (165). Lipoprotein lipase (LPL) is the key enzyme that hydrolyzes lipoproteins to release FA. Thus, when lipoproteins are hydrolyzed by LPL, a large amount of FA are released and are believed to be the principle source of FA supplied to the heart (14, 237). LPL is produced in cardiomyocytes and subsequently secreted onto heparan sulfate proteoglycan binding sites on the myocyte cell surface (33, 68, 70). From here, LPL is transported onto comparable binding sites on the luminal surface of coronary endothelial cells (193). At these sites, LPL hydrolyzes TG-rich lipoproteins, such as very-low-density lipoprotein (VLDL) and chylomicrons, to release FA. Perfusion of working hearts with VLDL or chylomicrons, in the absence or presence of FA, has revealed that, compared with chylomicrons, VLDL is a poor substrate for LPL (100). In addition, utilization of chylomicrons was inhibited by free FA, which failed to affect cardiac VLDL utilization (100). Given the important role that LPL plays in regulating FA delivery, alteration in its level is able to change FA delivery and subsequent oxidation. Indeed, overexpression of LPL in the heart or skeletal muscle accelerates FA uptake (141, 260). Conversely, tissue-specific knockout of LPL in the heart switches the cardiac substrate selection preference to glucose (12, 13). Other than hydrolysis by LPL, lipoproteins can also be transported into the cardiac tissue with help of the lipoprotein receptor, with VLDL uptake through this mechanism being more substantial compared with chylomicrons (178). In perfused working hearts, inhibition of the lipoprotein receptor significantly reduced FA oxidation without altering FA uptake, suggesting that lipoprotein receptor mediated FA uptake channels FA toward oxidation, whereas LPL mediated FA uptake channels FA toward both oxidation and TG storage (178). FA transporters. Although FA can translocate into the cell through passive diffusion across the plasma membrane, FA 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 FA Uptake and Utilization Invited Review H1492 ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES uptake shows saturation kinetics and is inhibited by proteases (7, 158, 159, 230). Thus FA transporters are also likely required to support this process. In the heart, three FA transporters have been identified and these include CD36, FA transport protein (FATP), and FA binding protein plasma membrane (FABPpm) (157). Given that 55– 80% of FA transport was blocked using general transporter inhibitors (131, 158) and that overexpression of CD36 or FATP has been found to dramatically increase FA metabolism (47, 113), these FA transporters are believed to play a key role in FA delivery to the cardiac tissue. Regulation of FA transport proteins occurs through different mechanisms. In severe STZ-induced diabetes, expression of cardiac CD36 and FABPpm were augmented (152), suggesting transcriptional modification of these transporters. At present, the mechanisms that induce this change have yet to be elucidated. Additionally, because muscle contraction or acute insulin treatment does not change protein but simply relocates CD36 from an intracellular pool to the sarcolemmal membrane (155, 156), posttranslational regulation of this transporter has also been suggested. Acyl-CoA synthase. Acyl-CoA synthase (ACS) catalyzes the esterification of FA to fatty acyl-CoA, the initial step of FA metabolism. Fatty acyl-CoA can be transported into the mitochondria for oxidation or used for intracellular TG synthesis. The fate of fatty acyl-CoA is influenced by the location of different ACS isoforms, energy demand, and the availability of FA (37). Moreover, ACS not only functions as an enzymecatalyzing esterification but is also actively involved in controlling FA homeostasis (48). Recent studies have demonstrated that ACS is associated with CD36 or FATP on the cytosolic side of the sarcolemmal membrane (84, 201, 214), suggesting that ACS also influences FA uptake. Several studies also suggest that FATP1 is a very long chain ACS (53). Overexpression of ACS in the heart or fibroblast causes dramatically augmented FA uptake and intracellular TG accumulation (48). AJP-Heart Circ Physiol • VOL Under normal conditions, 70 –90% of the esterified FA that enters cardiomyocytes is oxidized for ATP generation, whereas 10 –30% is converted to TG (228). The TG pool is not static, with lipolysis and esterification taking place continuously (240). In a normal heart, intracellular TG level is constant, indicating a balance of lipogenesis and lipolysis (210). In situations where FA supply supercedes the cellular oxidative capacity, such as obesity or diabetes, intracellular TG accumulates and is associated with lipotoxicity (240). Although TG is unlikely to be a direct mediator of cell apoptosis, its augmented lipolysis expands fatty acyl-CoA levels, which may be a key factor mediating cell apoptosis (117, 240). Thus TG is often used as a marker of lipotoxicity. PPARs. PPARs are a group of ligand-activated transcriptional factors belonging to the superfamily of nuclear receptors. They are activated by either natural ligands like FA or numerous pharmacological ligands (80). Once activated, PPARs form complexes with retinoid X receptors and bind to the promoter regions of a number of target genes that encode the proteins involved in controlling FA metabolism (76, 78). Through regulation of expression of these genes, PPARs modulate FA utilization at the transcriptional level. PPARs have three isoforms: PPAR-␣, PPAR- (or -␦), and PPAR-␥. PPAR-␣ is extensively expressed in tissues with high FA metabolism like the heart (17). Activated by elevated intracellular FA levels, PPAR-␣ promotes expression of genes that regulate FA oxidation at various steps, such as FA uptake and binding (LPL, CD36, and FA binding protein), FA esterification (ACS), and FA oxidation (carnitine palmitoyltransferase-1, acyl-CoA oxidase, long-chain acyl-CoA dehydrogenase, and very-long-chain acyl-CoA dehydrogenase) (76, 78, 111). Knocking out cardiac PPAR-␣ abolishes fasting-induced overexpression of FA metabolic genes and switches substrate selection from FA to glucose (140, 172). Overexpression of cardiac PPAR-␣ augments FA uptake and oxidation (77, 79). Taken together, PPAR-␣ is believed to be the primary regulator of FA metabolism in the heart. Similar to PPAR-␣, PPAR- 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 Fig. 2. Control of fatty acid (FA) delivery and utilization in the cardiomyocyte. FA, either from adipose tissue or released from triglyceride (TG)-rich lipoproteins through hydrolysis by lipoprotein lipase (LPL), is taken up into the cardiomyocyte by three FA transporters: CD36, FA transport protein (FATP), and FA binding protein plasma membrane (FABPpm). FA is converted to fatty acyl-CoA, which is transported into the mitochondria through CPT1/CPT2. Inside the mitochondria, fatty acyl-CoA undergoes -oxidation to generate acetyl-CoA, which is further oxidized in the tricarboxylic acid cycle. Utilization of FA is regulated through different mechanisms. FA, through activation of peroxisome prolferator-activated receptor-␣ (PPAR␣), increases the expression of a number of enzymes involved in FA oxidation. MalonylCoA, which is generated through carboxylation of acetyl-CoA catalyzed by acetyl-CoA carboxylase (ACC), inhibits CPT-1 and FA oxidation. AMP-activated kinase (AMPK) inhibits ACC, relieves its inhibition on CPT-1, and promotes FA oxidation. Similarly, malonyl-CoA decarboxylase (MCD), through decreasing malonylCoA by decarboxylating it to acetyl-CoA, enhances CPT-1 and FA oxidation. Invited Review ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES lumen LPL activity (8). Interestingly, recent studies using transgenic mice with a dominant negative form of AMPK has demonstrated that the lack of AMPK does not affect cardiac metabolism under physiological conditions (209, 259). At present, it is unclear as to what compensatory mechanisms are activated following knockout of AMPK. Additionally, it is unknown whether overexpression of AMPK could affect cardiac lipid homeostasis and metabolism. Malonyl-CoA decarboxylase. In addition to AMPK, malonyl-CoA decarboxylase (MCD) is also known to promote FA oxidation through its lowering of malonyl-CoA. MCD catalyzes the degradation of malonyl-CoA to acetyl-CoA, leading to reduction of malonyl-CoA (65). This action relieves the inhibition of CPT-1 by malonyl-CoA and favors FA oxidation. Recent studies have suggested that inhibition of cardiac MCD leads to accumulation of malonyl-CoA and reduced FA oxidation (66). Interaction Between Glucose and FA Metabolism Regulation of glucose and FA metabolism does not occur independently, and numerous studies have reported a “crosstalk” between the utilization of these substrates (Fig. 3) (199, 211, 233). Randle et al. (199) demonstrated that FA impairs basal and insulin-stimulated glucose uptake and oxidation, an event that is known as the “Randle cycle” (199). FA influences glucose utilization at multiple levels. Accumulation of FA impairs insulin-mediated glucose uptake through inhibition of insulin receptor substrate and protein kinase B (94, 115, 187). Accumulation of FA leads to augmented intracellular FA derivatives, such as fatty acyl CoA, diacylglycerol, and ceramide. These FA metabolites activate a serine kinase cascade, which involves protein kinase C- and IB kinase- (inhibitor of NF-B kinase-), leading to serine phosphorylation of IRS (129, 269). Serine phosphorylation of IRS-1 reduces tyrosine Fig. 3. Inhibition of glucose oxidation by FA utilization. Accumulation of FA impairs insulin-mediated glucose uptake through inhibition of insulin receptor substrate (IRS) and protein kinase-B (PKB). Increased intracellular FA also activates PPAR-␣. As a consequence, PPAR-␣ promotes the expression of genes involved in FA oxidation, as well as PDK4, known to inhibit PDH and pyruvate flux. Increased acetyl-CoA and NADH caused by the high rate of FA oxidation activate PDK4, leading to further inactivation of PDH. Augmented acetyl-CoA also causes accumulation of citrate in the cytosol, which subsequently inhibits PFK1 and glycolysis. AJP-Heart Circ Physiol • VOL 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 (or -␦) is expressed abundantly in the cardiac tissue (17). Activated by elevated intracellular FA (45), PPAR- (or -␦) augments expression of a group of genes that promote FA utilization (63, 169). Cardiac-specific knockout of PPAR- also decreases FA oxidative gene expression and FA oxidation (46). Although the targets of PPAR-␣ and PPAR- are partially overlapping (169), their unique roles and interaction remains unclear in the heart. PPAR-␥, the third number of the PPAR family, is highly expressed in adipose tissue. Through promoting lipogenic gene expression, PPAR-␥ controls lipogenesis. Loss and gain of function experiments have demonstrated that PPAR-␥ is necessary for adipose tissue proliferation and differentiation (16, 238). In isolated cardiomyocytes, the expression of PPAR-␥ is barely detectable (89), suggesting a limited direct role for this nuclear receptor in regulating cardiac metabolism. However, the ability of PPAR-␥ agonists to normalize elevated plasma concentrations of glucose and FA in diabetic animals will have a profound indirect effect on cardiac metabolism. AMP-activated protein kinase. As an energy sensor, AMPactivated protein kinase (AMPK) is activated following a rise in the intracellular AMP-to-ATP ratio (97). Once stimulated, AMPK switches off energy-consuming processes like protein synthesis, whereas ATP-generating mechanisms, such as FA oxidation and glycolysis, are turned on (96, 105). In heart and skeletal muscle, AMPK facilitates FA utilization through its control of acetyl-CoA carboxylase (ACC) (133, 134). As ACC catalyzes the conversion of acetyl-CoA to malonyl-CoA, AMPK by inhibiting ACC is able to decrease malonyl-CoA and minimize its inhibition of CPT-1, the rate-limiting enzyme-controlling FA oxidation. AMPK has also been implicated in FA delivery to cardiomyocytes through its regulation of the FA transporter CD36 (155). Additionally, results from our laboratory have demonstrated a strong correlation between activation of whole heart AMPK and increases in coronary H1493 Invited Review H1494 ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES ALTERATION OF CARDIAC METABOLISM DURING DIABETES Changes in Plasma Substrates Glucose and lipids are the major substrates affected by diabetes. Hyperglycemia is a consequence of decreased glucose clearance and augmented hepatic glucose production, whereas enhanced lipolysis in adipose tissue and higher lipoprotein synthesis in the liver dramatically increases circulating free FA and TG. Because glucose entry into the cell is largely dependent on insulin, whereas FA transport across plasma membrane does not require any hormone, the augmented circulating lipids increase FA delivery to the cardiomyocyte. With the increase of intracellular FA, cardiac tissue rapidly adapts to promote FA utilization. In addition to diabetes, augmentation of plasma lipids by fasting or intralipidheparin infusion also increases cardiac FA oxidation (52, 266). Under conditions where FA supply supercedes the oxidative capacity of the heart, the FA is converted to lipids like TG or ceramide, with an end result being lipotoxicity (272). In obese ZDF rats, lowering of plasma lipids with a PPAR-␥ agonist reduced cardiac TG and ceramide and improved heart function (272). Overall, these studies suggest that alterations in plasma lipids may drive changes in cardiac metabolism. It should be noted that a recent study using 4-wk-old ob/ob and db/db mice demonstrated altered cardiac metabolism without any change in plasma substrates (30). Hence, in these genetic mice models, intrinsic changes in the cardiomyocyte, rather than changes in circulating substrates, initiate alterations in cardiac metabolism at this early time point. Defects in Cardiac Carbohydrate Utilization In the obese or diabetic heart, myocardial glucose utilization is compromised at several points. In noninsulin-controlled Type 1 diabetic animals, reduced GLUT gene and protein expression compromises cardiac glucose uptake and oxidation (34). In obese or Type 2 diabetic animals, although there is hyperglycemia and hyperinsulinemia, cardiac glucose uptake is reduced as a consequence of reduced GLUT4 protein and impaired insulin signaling (38, 266). With the use of ob/ob and db/db mice, a recent study (30) reported that cardiac glucose oxidation is reduced at 4 wk of age and was associated with increased FA oxidation. Interestingly, this lower glucose oxidation occurred before the onset of impaired insulin signaling in the heart and development of hyperglycemia. Thus this early AJP-Heart Circ Physiol • VOL reduction in glucose utilization is likely due to suppression by high FA oxidation rather than impaired cardiac-specific insulin signaling. In another study that used db/db mice at different ages, increased cardiac FA oxidation preceded the reduction in glucose oxidation (5). Higher FA oxidation increases citrate, which is known to inhibit PFK, the rate-limiting enzyme in glycolysis. Elevated intracellular FA is also known to increase PDK-4 expression, which phosphorylates and inhibits PDH. Finally, high rates of FA oxidation augment acetyl-CoA that inhibits PDH either allosterically or through activation of PDK. When compared with animal models, the use of carbohydrates in the human diabetic hearts is more controversial. In Type 1 diabetic patients, decreased myocardial carbohydrate uptake is reported (15, 62). With the use of an euglycemic insulin clamp, another study (179) has shown that cardiac glucose uptake is normal in these patients, suggesting that insulin is the major limiting factor that influences cardiac glucose uptake and no cardiac-specific insulin resistance is evident, as observed in skeletal muscle. In Type 2 diabetes, cardiac expression of GLUT4 is compromised likely due to elevated FA (10). However, a number of studies have also reported that cardiac tissue from Type 2 diabetic patients respond normally to insulin and show regular glucose uptake, suggesting that myocardial insulin resistance is not a common feature of Type 2 diabetes (118, 160, 242). Interestingly, a recent study has suggested that impaired myocardial glucose uptake is only observed in Type 2 diabetic patients with hypertriglyceridemia, suggesting that myocardial insulin resistance in these patients is associated with hypertriglyceridemia and augmented plasma FA levels (168). Cardiac lactate utilization is also compromised following diabetes. In STZ-induced Type 1 diabetes, cardiac utilization of lactate is reduced to a greater extent when compared with glucose oxidation (41, 42). Moreover, hearts from 12-wk-old ZDF rats also showed lower carbohydrate oxidation, and this was almost entirely due to a reduction in lactate rather than glucose oxidation (43, 250). The mechanisms that mediate the inhibition of lactate utilization are unclear but is likely independent of any alterations in lactate dehyrogenase or lactate transporter (41). The shift of cardiac energy substrate utilization from carbohydrate to lipids increases the intracellular glycogen pool, probably through augmented glycogen synthesis, or impaired glycogenolysis, or a combination of both processes (103, 136, 167, 223). Emerging evidence indicates that glycogen, in addition to its role as energy storage, is also able to regulate metabolism. At least in skeletal muscle, accumulation of glycogen acutely alters glycogen synthesis and glucose metabolism (59, 120 –122). Chronically, glycogen accumulation may also impair insulin signaling in skeletal muscle (121). Whether cardiac glycogen accumulation also influences insulin signaling and metabolism is unknown. In addition, recent studies have identified a glycogen-binding domain in the -subunit of AMPK and suggests that this domain links AMPK and glycogen (108). Although an association between high glycogen levels and repressed AMPK activity in human and rat skeletal muscle have been documented (254, 255), it is still unclear whether glycogen is able to regulate metabolism through AMPK. 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 phosphorylation and interferes with its ability to phosphorylate and activate phosphatidylinositol 3-kinase and protein kinase B (206). Increased intracellular FA also activates PPAR-␣. As a consequence, PPAR-␣ promotes the expression of genes involved in FA oxidation, as well as pyruvate dehydrogenase kinase-4 (PDK4), which is known to inhibit PDH and pyruvate flux (257). Moreover, increased acetyl-CoA-to-free CoA and NADH-to-NAD⫹ ratios caused by the high rate of FA oxidation are also known to activate PDK4, leading to inactivation of PDH (29, 104). Augmented acetyl-CoA-to-free CoA ratio also causes accumulation of citrate in the cytosol, which subsequently inhibits PFK and glycolysis (85, 175). Conversely, inhibition of FA oxidation through elevation of malonyl-CoA levels, or using pharmacological inhibitors, favors glucose oxidation. Invited Review ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES Alterations in FA Utilization AJP-Heart Circ Physiol • VOL expression of VLDL receptor decreases following STZ-induced diabetes (116). FA transporters. During obesity and diabetes, the high rate of FA uptake is facilitated by FA transporters, leading to augmented FA oxidation and TG storage. In STZ-induced diabetes, the increase in plasmalemmal CD36 and FABPpm amplifies FA uptake, an effect resulting from increased CD36 and FABPpm protein expression (152). In Zucker fatty rats, without a change in total protein, permanent relocation of CD36 and FABPpm to the cardiomyocyte plasmalemmal membrane augments FA uptake (55, 56, 153). The mechanism for this permanent repositioning of FA transporters at the plasma membrane is still unknown. Interestingly, in young (4 wk) ob/ob or db/db mice, cardiac FA oxidation increases without any change in circulating substrates (30). Given that the high rate of FA oxidation requires coordinated FA uptake, augmentation of CD36-mediated FA supply is suggested to be involved in facilitating FA oxidation at this early stage of insulin resistance. PPAR-␣. As the principle regulator of cardiac FA metabolism, PPAR-␣ plays an important role in controlling FA oxidation during obesity and diabetes. Activation of this nuclear receptor in the heart has been reported in almost all obese or diabetic animal models, including STZ-induced diabetic rats, ZDF rats, and ob/ob and db/db mice (30, 79, 220). Given that FA and its derivatives activate PPAR-␣, higher cardiac PPAR-␣ activity is always observed when circulating lipids are augmented (30, 171). Hence, in ob/ob and db/db mice, activation of PPAR-␣, evidenced by elevated expression of its downstream targets, is only observed at 12 wk and is associated with augmented plasma lipid (30). A similar association between plasma lipids and PPAR-␣ is also seen in hearts from STZ-induced diabetic rats, with only chronic (6 wk) but not acute (4 days) diabetes demonstrating activation of PPAR-␣ (unpublished data). Interestingly, in acute STZ diabetes or 4-wk ob/ob or db/db mice, increased FA oxidation is observed even in the absence of any change in cardiac PPAR-␣ and its downstream targets, suggesting PPAR-␣ independent control of FA oxidation. Identification of these mechanisms requires further studies. After activation, cardiac PPAR-␣ promotes the expression of a group of genes involved in various steps of FA oxidation. Simultaneously, activation of PPAR-␣ also reduces expression of genes involved in glucose uptake, glycolysis, and oxidation through direct or indirect mechanisms (77, 79). With the use of transgenic mice, a recent study (186) demonstrated that knocking out cardiac PPAR-␣ prevented suppression of GLUT4 expression and glucose uptake by elevated plasma FA and improved myocardial recovery from ischemia following STZ diabetes induction, high-fat feeding, or fasting. Taken together, activation of cardiac PPAR-␣ not only favors FA oxidation but also inhibits glucose uptake and utilization, leading to augmented susceptibility to ischemic damage. MCD. In STZ-induced diabetes, overexpression of cardiac MCD protein was observed and could contribute to the high rate of FA oxidation (213). It is unknown whether MCD also plays a role in augmenting cardiac FA oxidation in obese and Type 2 diabetes. Nevertheless, given that PPAR-␣ increases MCD expression (138, 265), higher MCD protein levels are expected following PPAR-␣ activation during obesity and Type 2 diabetes. 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 Utilization of FA by cardiac tissue increases following obesity and diabetes. This change occurs not only as a consequence of increased FA supply but also through an intrinsic adaptation/maladaptation to elevated FA (234, 267). It must be acknowledged that some studies have also observed a reduced, rather than augmented, FA oxidation in Zucker fatty or ZDF rats (266, 272). In human diabetic patients, obese women demonstrate increased FA utilization, associated with augmented cardiac oxygen consumption, and reduced cardiac efficiency (190). Moreover, elevated cardiac TG and increased expression of PPAR-␣ target genes have been observed in patients without ischemic heart disease, very similar to lipotoxic ZDF rat hearts (220). Lipoprotein lipase. The amount of FA supplied to the heart through LPL is influenced by multiple factors, including LPL activity and plasma lipoprotein concentration and composition. The relative contribution of cardiac LPL activity to the delivery of free FA to the diabetic heart is inconclusive. Thus LPL immunoreactive protein or activity has been reported to be unchanged, increased, or decreased in the diabetic rat heart. In part, this variability between different studies could be due to the diversity in the rat strains used, the dosage of STZ used to induce diabetes, and the duration of the diabetic state (203). In addition, many of the above investigations utilized procedures that did not distinguish between functional (i.e., heparin-releasable component localized on capillary endothelial cells that is implicated in the hydrolysis of circulating TG) and cellular (i.e., non-heparin-releasable pool that represents a storage form of the functional enzyme) pools of cardiac LPL because cellular LPL activity or protein levels have largely been obtained using whole heart homogenates. Rodrigues et al. (203) have previously reported that in STZ (55 mg/kg)-induced moderate diabetic Wistar rat hearts, HR-LPL activity is significantly increased. Induction of more severe diabetes using 100 mg/kg STZ did not influence HR-LPL (203). In another study using hearts from 65 mg/kg STZ-induced diabetic rats, HR-LPL decreased and was associated with reduced VLDL-TG lipolysis (182). Acute treatment of these diabetic rats with insulin enhanced both HR-LPL and VLDL-TG lipolysis (182). In mouse models of diabetes, although there is no change of cardiac HR-LPL activity in either STZ or db/db hearts, utilization of chylomicron-TG increases (174). Hence, the mechanisms that control cardiac LPL during diabetes are complex and have yet to be completely resolved. It should be noted that even though LPL may not change following obesity or diabetes, increased circulating lipoproteins through LPL cleavage could still elevate FA supply to the cardiac tissue. However, increased concentration could be offset by changes in lipoprotein composition or lipoprotein receptor number. Binding of lipoproteins containing apolipoprotein (apo) CII to LPL enhances lipolysis (181), whereas binding of lipoproteins containing apoCIII or apoE suppresses LPL activity (1, 2). A recent study has shown that overexpression of HDL-associated apo AV accelerates hydrolysis of TG-rich lipoproteins, indicating the importance of this apo lipoprotein in stimulating LPL (166, 188). O’Looney et al. (181) have shown that induction of diabetes by STZ changes lipoprotein composition, with reduced apoCII levels, leading to impaired VLDL-TG lipolysis. A recent study has reported that H1495 Invited Review H1496 ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES Limitations of Metabolic Measurements Using Radiolabeled Substrate CONSEQUENCES OF ALTERED METABOLISM IN DIABETIC HEARTS Impaired Cardiac Function Emerging evidence supports the concept that alterations in metabolism contribute toward cardiac contractile dysfunction. In STZ-induced diabetes, a larger number of studies have implicated metabolic abnormalities (FA oxidation provides almost 100% of ATP, with a dramatic decrease of glucose utilization) in cardiac contractile dysfunction (219, 227, 234, 267). In these animals, contractile failure begins as diastolic dysfunction, followed by severe systolic dysfunction (196, 219). Normalizing energy metabolism in these hearts reverses the impaired contractility (40, 176, 248). Animal models of obesity and Type 2 diabetes also exhibit cardiac dysfunction associated with altered cardiac metabolism (5, 21, 218). Some studies have observed both impaired diastolic and systolic function (3, 218), whereas other studies argue that no change in systolic function is present (6, 18, 164, 197). This discrepancy could be due to the severity of diabetes or the methods used to evaluate cardiac function. In diabetic patients, left ventricular hypertrophy and impaired isovolumic relaxation and ventricular filling are the most common abnormalities diagnosed (196). During diabetes, changes in cardiac metabolism occur early and precede the development of cardiomyopathy. For example, in STZ-induced diabetes, altered cardiac metabolism is observed as early as 4 days following diabetes induction (88), whereas evidence of cardiomyopathy is only apparent after 4 – 6 wk. Similarly, in ob/ob and db/db mice, changes in cardiac metabolism are evident much before confirmation of cardiac dysfunction (5, 30). To validate the role of altered metabolism in provoking cardiac dysfunction, several studies have treated 6- or 9-wk-old db/db mice with either PPAR-␣ or AJP-Heart Circ Physiol • VOL 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 The majority of metabolic data in the above studies were obtained by using radiolabeled substrate perfusion of isolated hearts. In these methods, [3H]glucose and [14C]glucose were used to evaluate glycolysis and glucose oxidation, whereas [3H]FA or [14C]FA was used to estimate FA oxidation by measuring the generation of 3H2O and 14CO2. Although this measurement allows for the manipulation of substrate concentration, there are limitations. First, the substrates used in perfused hearts do not truly reflect what the heart receives in vivo. For example, lipoproteins, lactate, and ketone bodies that are important substrates for the heart in vivo (39, 98, 165) are rarely used to examine metabolism in perfused hearts. In addition, most metabolic data of diabetic hearts are obtained by using normal concentrations of glucose and/or palmitate, which differ from the elevated concentrations seen in the diabetic conditions in vivo. Another drawback is that diabetic hearts always have an elevated intracellular TG pool. Augmented intracellular TG turnover in diabetic hearts could dilute utilization of exogenous radiolabeled palmitate oxidation, resulting in an underestimation of FA oxidation (180). Finally, hormonal effects on energy metabolism are usually not considered (20), and lack of hormones in the in vitro perfusate may contribute to functional abnormalities that are not recapitulated in intact models. PPAR-␥ agonists for 3– 6 wk (3, 4, 36). Even though these treatments normalized cardiac metabolism, they failed to improve cardiac function in these mice, suggesting that metabolism may be unrelated to heart failure or that the treatment was not initiated in time. Interestingly, when ZDF rats were treated with a PPAR-␥ agonist at 6 wk of age [when insulin resistance compared with 6-wk-old db/db mice is milder (37)], improvements of cardiac metabolism and heart function were observed (272). In a different study, changing cardiac metabolic profile by treating ZDF rats with PPAR-␥ agonist also improved contractile function (91). Additionally, overexpression of GLUT4 in db/db mice not only normalized cardiac metabolism but also improved heart function (21, 218). These studies suggest that acute changes in metabolism likely induce early and reversible damage to cardiac tissue. Even though these early alterations are inadequate to produce cardiac functional changes, early interventions would be favored to provide protection against development of cardiomyopathy in the later stages of the disease. The role of abnormal cardiac metabolism in cardiac dysfunction is also supported by studies using transgenic mice. Overexpression of cardiac PPAR-␣ increased FA uptake and oxidation (79). The hearts from these transgenic mice exhibit a metabolic phenotype similar to diabetic hearts (79). Measurement of heart function revealed systolic dysfunction and ventricular hypertrophy in these hearts, indicating that, in the absence of systemic metabolic disturbances, alteration of cardiac metabolism is sufficient to induce cardiac contractile dysfunction (79). This concept is further substantiated by transgenic mice overexpressing cardiac ACS, FATP1, or LPL (47, 48, 260). These transgenic mice have shown increased FA uptake, utilization, or lipid accumulation, and these changes correlated well with contractile dysfunction. In contrast, several studies have reported that altered metabolism has no impact on contractile function (224, 250). It should be noted that, in these studies, heart function was evaluated using a Langendorff heart perfusion. Given that diabetic hearts exhibit reduced mitochondrial oxidative capacity and cardiac efficiency (28, 106), it is possible that with increased workload and energy requirement, cardiac function would be compromised. In addition to heart dysfunction per se, diabetic patients also have a greater incidence and severity of angina and acute myocardial infarction (147). After a myocardial infarction, diabetic patients have almost twice the rate of mortality compared with nondiabetics (229). Alterations in myocardial energy metabolism during diabetes are probably an important contributing factor in explaining this increased susceptibility to ischemic damage. In obese or diabetic animals, increased ischemic damage is also observed (5, 60, 93, 147), and normalization of cardiac metabolism in hearts from these animals has been shown to improve functional recovery following ischemia-reperfusion (147, 224, 270). Interestingly, a number of studies have also reported contradictory results, with decreased susceptibility to ischemia-reperfusion damage being reported in STZ or ZDF hearts (145, 150, 236, 249). Although the mechanisms for this observation are still unclear, decreased glycolysis and glycolytic products, a lower Na⫹-Ca2⫹ activity, and a decreased clearance of protons via the Na⫹/H⫹ exchanger have been proposed to explain this inconsistency (75). Invited Review ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES H1497 Although changes in metabolism have been implicated in diabetic cardiac dysfunction, the mechanisms responsible are still unclear. Several factors have been proposed, and these include changes in Ca2⫹ homeostasis, decreased cardiac efficiency, lipotoxicity, and myocardial mitochondrial damage (Fig. 4). been documented (215, 271). Irrespective of the mechanism, suppression of SERCA2a and the Na⫹/Ca2⫹ exchanger results in poor calcium handling associated with impaired heart function (6, 22, 49). Interestingly, overexpression of SERCA2a in the diabetic heart improved Ca2⫹ handling (243) and cardiac function (239). Effects on Ca2⫹ Homeostasis Decreased Cardiac Efficiency When compared with glucose, oxidation of FA consumes more oxygen (2.58 vs. 2.33 ATP/oxygen atom). Cardiac efficiency, the ratio of cardiac work to myocardial oxygen consumption, changes with the type of substrate. Thus, in perfused hearts, provision of FA decreases cardiac efficiency compared with when glucose is the sole substrate (31, 162, 245). Additionally, decreased cardiac efficiency is also observed in human or experimental animals with obesity or diabetes (106, 162, 191). This reduction in cardiac efficiency and increased oxygen demand makes the heart especially vulnerable to damage following increased workload or ischemia. Interestingly, even though oxidation of FA requires 10% more oxygen compared with glucose, cardiac oxygen consumption is over 30% higher in ob/ob or db/db mice compared with control hearts, suggesting that other mechanisms also contribute to higher oxygen consumption and lower cardiac efficiency (37). A recent study reported oxygen wasting for noncontractile purposes in the diabetic heart (106). The mechanisms for this oxygen wasting are unknown, and uncoupled proteins (UCPs) are suggested as a potential target. In hearts from STZ-induced diabetic rats and ob/ob and db/db mice, augmented gene expression or protein levels of UCP2 or UCP3 have been reported (30, 102, 170, 171, 268). Other studies demonstrate no association between change in cardiac UCP protein levels and the onset of cardiac inefficiency (28, 30). Hence, additional studies are required to identify the targets that cause oxygen wasting observed in hearts from obese and diabetic animals. Lipotoxicity Fig. 4. Consequences of changes in cardiac metabolism during diabetes. After insulin resistance or diabetes, augmented cardiac FA uptake promotes FA utilization and storage, which contributes toward a reduction in glycolysis and glucose oxidation. As ATP generated through glycolysis is preferentially used by ion transporters (like Ca2⫹-ATPase), inhibition of cardiac glycolysis impairs intracellular Ca2⫹ homeostasis. High rate of FA oxidation increases reactive oxygen species (ROS) generation, along with augmented lipid storage, leading to lipotoxicity and mitochondrial dysfunction. High rate of FA oxidation also increases oxygen demand and reduces cardiac efficiency. All of these changes can eventually contribute to the development of diabetic cardiomyopathy. AJP-Heart Circ Physiol • VOL A number of studies have suggested that excessive FA overload induces lipotoxicity and contributes to the initiation and development of cardiomyopathy (194, 272). With the use of transgenic mice, studies have shown that elevation of FA uptake or utilization induces lipotoxicity in the absence of any systemic metabolic disturbance. Cardiac-specific overexpression of LPL or FATP1 significantly increased FA delivery with ensuing lipid storage, lipotoxic cardiomyopathy, and contractile dysfunction (47, 260). Moreover, elevating FA utilization by cardiac-specific overexpression of PPAR-␣ or ACS also causes cardiomyopathy and cardiac dysfunction, similar to that seen during diabetes (48, 79). Conversely, reducing FA supply or utilization prevented the development of cardiomyopathy in obese or diabetic animals. In ZDF or transgenic mice with cardiac overexpression of LPL, a PPAR-␥ agonist decreased plasma and cardiac intracellular lipids and ameliorated cardiomyopathy (244, 272). A recent study also demonstrated that increasing lipoprotein excretion by overexpressing human apoB reduced cardiac lipids and improved cardiomyopathy (264). Taken together, these studies provide convincing evidence that augmented FA supply during obesity or diabetes impairs cardiac lipid homeostasis and leads to lipotoxicity cardiomyopathy. 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 Within the cell, enzymes that catalyze glycolysis are located close to the sarcoplasmic reticulum and sarcolemma (71, 251), and ATP generated through glycolysis is preferentially used by ion transporters [like Ca2⫹-ATPase (SERCA2a) and Na⫹-K⫹ATPase] in these membrane fractions (71, 228, 252). Thus inhibition of cardiac glycolysis by high rates of FA oxidation during obesity and diabetes may impair intracellular Ca2⫹ homeostasis, a defect that has been proposed to contribute toward the development of cardiomyopathy. Altered Ca2⫹ homeostasis can also result from glycolysis-independent mechanisms. For example, decreased cardiac expression of SERCA2a or Na⫹/Ca2⫹ exchanger have been observed in Type 1 (99, 126) and Type 2 diabetic animals (22). Although the mechanisms for this reduction in gene expression are unclear, several studies have suggested that accumulation of glucose metabolites due to dissociation of glucose influx and pyruvate oxidation plays a role (51). Conversely, decreasing glucose metabolites has been shown to prevent the decrease in SERCA2a following diabetes (207). In other studies, a decrease in the activity of SERCA2a and Na⫹/Ca2⫹ exchanger, without any change in expression or protein levels, have also Invited Review H1498 ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES Hyperglycemia In addition to hyperlipidemia-induced lipotoxicity, hyperglycemia also provokes glucotoxicity, which could contribute to cardiac tissue injury. Hyperglycemia promotes the producAJP-Heart Circ Physiol • VOL tion of reactive oxygen and nitrogen species, leading to cytochrome c-mediated caspase 3 activation and myocardial apoptosis (32). Hyperglycemia-induced oxidative stress also activates poly(ADP-ribose) polymerase-1 (PARP) (64). Mild activation of PARP regulates multiple cellular reactions such as DNA repair, gene expression, and cell survival (246). However, overactivation of PARP could initiate a series of cellular processes, leading to cellular damage. Through depletion of NAD⫹, an ATP-consuming process, PARP may cause energy deficit and cell death (69). PARP, through inhibition of glyceraldehyde phosphate dehydrogenase (GAPDH), diverts glucose from glycolytic pathways into alternative fates, including advanced glycation end product (AGE) formation, hexosamine, polyol pathway flux, and protein kinase C (PKC) activation, which are believed to mediate hyperglycemia-induced cardiac tissue damage (64, 196). In this regard, increased formation of AGE forms irreversible cross-links with many macromolecules such as collagen, leading to tissue fibrosis, inactivation of SERCA2a, and ryanodine receptor calciumrelease channel, impaired cardiac relaxation, contractility, and ventricular stiffness (26, 27, 35, 54). Increased hexosamine influx reduces SERCA2a protein levels, resulting in prolonged calcium transients and delayed myocardial relaxation (51). Increased hexosamine influx also impairs insulin signal transduction and contributes to insulin resistance (163). Increased polyol flux is associated with a decrease in intracellular glutathione levels and an augmentation in cell apoptosis (83). Conversely, inhibition of polyol flux protects hearts from ischemic injury (125, 198). Finally, activation of PKC-2 leads to left ventricular hypertrophy, cardiac myocyte necrosis, multifocal fibrosis, and decreased left ventricular performance, resulting in cardiomyopathy (247). Taken together, hyperglycemia, through multiple pathways, causes cardiac cellular and functional changes, possibly contributing to the development of cardiomyopathy. Mitochondrial Dysfunction Mitochondria are the primary source of energy generation within cells. Acetyl-CoA generated from FA -oxidation or glycolysis is used by the tricarboxylic acid cycle for production of NADH and FADH2. These electron carriers transfer electrons to the mitochondria electron transport chain, where ATP is ultimately generated. Thus cardiac mitochondrial dysfunction is expected to induce deleterious cellular effects, ultimately leading to heart disease. Indeed, humans with inherited or acquired mitochondrial defects develop cardiomyopathy (112, 208). With the use of transgenic mice models, mitochondrial dysfunction is also associated with heart disease. For instance, knock out of Ant1 (which controls exchange of mitochondrial ATP with cytosolic ADP) or Tfam (a mitochondrial transcription factor that regulates mitochondrial biosynthesis and gene expression) results in a cardiac energy deficit and cardiomyopathy (92, 142). Mice with cardiac-specific deletion of mitochondrial genes involved in FA oxidation also display a cardiomyopathic phenotype (72, 135). Interestingly, the opposite is also true with overexpression of PPAR-␣ (which regulates the expression of mitochondrial enzymes involved in FA oxidation) (79) or PGC1 (which controls mitochondrial biosynthesis) (139) resulting in mitochondrial dysfunction and cardiomyopathy. In Type 1 or Type 2 diabetic 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 Although limited evidence is available of the existence of lipotoxicity in human diabetic patients, some studies have documented similarities between rodent lipotoxicity and the human metabolic syndrome (240). In a subgroup of patients with heart failure, Sharma et al. (220) have identified severe metabolic dysregulation characterized by intracellular TG accumulation and alterations in gene expression, similar to the lipotoxic rat heart. Increased apoptosis was also detected in ventricular biopsies from Type 2 diabetic patients (82). Additionally, cardiac PCr-to-ATP ratio was decreased in Type 2 diabetic patients and correlated well with plasma FA concentrations (216). The mechanisms that mediate cardiac lipotoxicity are still not completely understood. One potential target is over production of ROS (79). High rate of FA oxidation increases mitochondrial action potential, leading to augmented ROS generation. Under normal physiological conditions, ROS is removed by cellular antioxidants. In the event of excessive generation of ROS, as observed in STZ-induced diabetic rats, ZDF rats, and db/db mice (19, 32, 272), it causes cardiomyocyte cell damage and augmented apoptosis. Another potential mechanism for lipotoxicity is accumulation of lipids, when FA uptake supercedes its oxidation. Regarding accumulation of TG, the role of this neutral lipid in inducing contractile dysfunction is still unknown, although a strong association between TG storage and lipotoxicity has been established in both animal models and human studies (50, 220, 272). Interestingly, a recent study suggested that TG formation actually provides protection against the deleterious effects of fatty acyl-CoA (144). Besides TG, excessive FA also leads to ceramide generation, an intracellular messenger known to trigger apoptosis (272). Accumulation of ceramide has been found in ZDF rats (272) or in isolated cardiomyocytes incubated with high fat (67, 101). Ceramide upregulates inducible nitric oxide synthase through activation of NF-B, leading to increased generation of nitric oxide and peroxynitrite (241, 272). As a highly reactive molecule, peroxynitrite causes opening of the mitochondrial permeability transition pore and release of cytochrome c. Additionally, ceramide directly interacts with cytochrome c, leading to its release from the mitochondria (87). As a consequence, caspase is activated, which initiates the apoptotic pathway in cells. Additionally, with the use of isolated cardiomyocytes, high FA impairs cardiolipin and leads to ceramide-independent cell apoptosis (184). Finally, accumulation of FA metabolites has also been associated with insulin resistance. FA derivatives, such as fatty acyl CoA, diacylglycerol, or ceramide may activate a serine kinase cascade, which involves protein kinase C- and IB kinase- (inhibitor of NF-B kinase-), leading to serine phosphorylation of IRS (44, 114, 128, 129, 269). Following this, tyrosine phosphorylation of IRS and its ability to activate phosphatidylinositol 3-kinase and protein kinase B are compromised (206). Future studies are required to substantiate the roles of these FA derivatives in the development of insulin resistance, especially in the heart. Invited Review ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES Summary In this review, we document that both insulin resistance and Type 1 and Type 2 diabetes exhibit similar alterations in cardiac metabolism through extrinsic and intrinsic mechanisms. The predominant change is a suppression of cardiac glucose utilization and a switch to excessive FA utilization associated with lipid storage. It should be noted that, in the majority of these studies, metabolic outcomes were obtained using ex vivo perfused working hearts. Additionally, only two substrates (glucose and fatty acid) were present in the perfusion buffer, and lactate, lipoproteins, ketone bodies, and relevant hormones were excluded. Hence, cardiac metabolism measured through this method may not reflect the in vivo situation. Despite these drawbacks, many studies have documented a strong correlation between altered cardiac metabolism and cardiac dysfunction observed during insulin resistance or diabetes. This correlation was further substantiated using transgenic mice with lipid oversupply in the absence of systemic interference. Regarding heart function, both diastolic and systolic dysfunction are observed in Type 1 diabetic animals. This is likely a consequence of prolonged hypoinsulinemia and hyperglycemia. With Type 2 diabetic models, there are conflicting reports, with some studies documenting both impaired systolic and diastolic function, whereas other studies argue against a change in systolic function. It is possible with Type 2 diabetic models, this discrepancy could be due to the severity or duration of hyperinsulinemia, and eventual hyperglycemia, or the techniques used to measure cardiac function. Finally, during diabetes, changes in cardiac metabolism occur early and precede the development of cardiomyopathy. Even though altered metabolism is inadequate to produce cardiac functional changes at this early time, it is likely that early metabolic damage is occurring at the cellular or subcellular levels. Overtime, these cumulative defects could be contributing to diabetic cardiomyopathy. Identification of this early damage could AJP-Heart Circ Physiol • VOL facilitate proper interventions and provide protection against development of diabetic cardiomyopathy in the later stages of the disease. GRANTS This work was supported by operating grants from Heart and Stroke Foundation of BC and Yukon and Canadian Diabetes Association. REFERENCES 1. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, and Breslow JL. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C.III transgenic mice Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 90: 1889 –1900, 1992. 2. Aalto-Setala K, Weinstock PH, Bisgaier CL, Wu L, Smith JD, and Breslow JL. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-I.I.I. transgenic mice. J Lipid Res 37: 1802–1811, 1996. 3. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen M, and Larsen TS. Cardiac function and metabolism in Type 2 diabetic mice after treatment with B.M 170744, a novel PPARalpha activator. Am J Physiol Heart Circ Physiol 283: H949 –H957, 2002. 4. Aasum E, Cooper M, Severson DL, and Larsen TS. Effect of BM 17 0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Can J Physiol Pharmacol 83: 183–190, 2005. 5. Aasum E, Hafstad AD, Severson DL, and Larsen TS. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 52: 434 – 441, 2003. 6. Abe T, Ohga Y, Tabayashi N, Kobayashi S, Sakata S, Misawa H, Tsuji T, Kohzuki H, Suga H, Taniguchi S, and Takaki M. Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol 282: H138 –H148, 2002. 7. Abumrad NA, Park JH, and Park CR. Permeation of long-chain fatty acid into adipocytes. Kinetics, specificity, and evidence for involvement of a membrane protein. J Biol Chem 259: 8945– 8953, 1984. 8. An D, Pulinilkunnil T, Qi D, Ghosh S, Abrahani A, and Rodrigues B. The metabolic “switch” AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am J Physiol Endocrinol Metab 288: E246 –E253, 2005. 9. Anguera I, Magrina J, Setoain FJ, Esmatges E, Pare C, Vidal J, Azqueta M, Garcia A, Grau JM, Vidal-Sicart S, and Betriu A. Anatomopathological bases of latent ventricular dysfunction in insulindependent diabetics. Rev Esp Cardiol 51: 43–50, 1998. 10. Armoni M, Harel C, Bar-Yoseph F, Milo S, and Karnieli E. Free fatty acids repress the GLUT4 gene expression in cardiac muscle via novel response elements. J Biol Chem 280: 34786 –34795, 2005. 11. Atkinson LL, Fischer MA, and Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 277: 29424 –29430, 2002. 12. Augustus A, Yagyu H, Haemmerle G, Bensadoun A, Vikramadithyan RK, Park SY, Kim JK, Zechner R, and Goldberg IJ. Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression. J Biol Chem 279: 25050 –25057, 2004. 13. Augustus AS, Buchanan J, Park TS, Hirata K, Noh HL, Sun J, Homma S, D’Armiento J, Abel ED, and Goldberg IJ. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 281: 8716 – 8723, 2006. 14. Augustus AS, Kako Y, Yagyu H, and Goldberg IJ. Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab 284: E331– E339, 2003. 15. Avogaro A, Nosadini R, Doria A, Fioretto P, Velussi M, Vigorito C, Sacca L, Toffolo G, Cobelli C, Trevisan R, E. Duner, R. Razzolini, F. Rengo, and G. Crepaldi. Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. Am J Physiol Endocrinol Metab 258: E606 –E618, 1990. 16. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, and Evans RM. PPARgamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4: 585–595, 1999. 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 rats, impaired mitochondrial function has been demonstrated (222, 262), an observation similar to hearts from transgenic mice. Given the similarity between transgenic mice and models of diabetes, these studies strongly suggest that impairment of mitochondrial function contributes to the development of cardiomyopathy. The mechanisms by which mitochondrial dysfunction contributes toward cardiomyopathy are still unclear. One potential target is ROS. Augmented ROS generation following high FA oxidation induces oxidative stress and cell damage. Inhibition of ROS by overexpression of metallothionein, MnSOD, or catalase has been shown to protect against mitochondrial dysfunction and cardiomyopathy (221, 262, 263). Another target is ceramide, a sphingolipid that has been shown to accumulate following FA overload. Ceramide, through inhibition of mitochondrial respiratory chain, or inducing cytochrome c release from mitochondria and apoptosis, is suggested to provoke the development of cardiomyopathy (67, 95). Augmented expression of PGC1 in hearts from obese or diabetic animals may increase mitochondrial proliferation, mitochondrial ultrastructural abnormalities and dysfunction, and ultimately cardiomyopathy (139). Finally, following end stage diabetes, dysfunction of mitochondria causes energetic starvation, leading to heart failure (208). H1499 Invited Review H1500 ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES AJP-Heart Circ Physiol • VOL 37. Carley AN and Severson DL. Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 1734: 112–126, 2005. 38. Carroll R, Carley AN, Dyck JR, and Severson DL. Metabolic effects of insulin on cardiomyocytes from control and diabetic db/db mouse hearts. Am J Physiol Endocrinol Metab 288: E900 –E906, 2005. 39. Chatham JC. Lactate–the forgotten fuel! J Physiol 542: 333, 2002. 40. Chatham JC and Forder JR. Relationship between cardiac function and substrate oxidation in hearts of diabetic rats. Am J Physiol Heart Circ Physiol 273: H52–H58, 1997. 41. Chatham JC, Gao ZP, Bonen A, and Forder JR. Preferential inhibition of lactate oxidation relative to glucose oxidation in the rat heart following diabetes. Cardiovasc Res 43: 96 –106, 1999. 42. Chatham JC, Gao ZP, and Forder JR. Impact of 1 wk of diabetes on the regulation of myocardial carbohydrate and fatty acid oxidation. Am J Physiol Endocrinol Metab 277: E342–E351, 1999. 43. Chatham JC and Seymour AM. Cardiac carbohydrate metabolism in Zucker diabetic fatty rats. Cardiovasc Res 55: 104 –112, 2002. 44. Chavez JA, Knotts TA, Wang LP, Li G, Dobrowsky RT, Florant GL, and Summers SAA. Role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 278: 10297–10303, 2003. 45. Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, Liao D, Han J, Kang H, and Evans RM. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100: 1268 –1273, 2003. 46. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, and Yang Q. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10: 1245–1250, 2004. 47. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, and Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96: 225–233, 2005. 48. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, and Schaffer JEA. novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107: 813– 822, 2001. 49. Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, Dilly KW, Guatimosim S, Lederer WJ, and Matlib MA. Defective intracellular Ca2⫹ signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am J Physiol Heart Circ Physiol 283: H1398 –H1408, 2002. 50. Christoffersen C, Bollano E, Lindegaard ML, Bartels ED, Goetze JP, Andersen CB, and Nielsen LB. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 144: 3483– 3490, 2003. 51. Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M, and Dillmann WH. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem 278: 44230 – 44237, 2003. 52. Clerk LH, Rattigan S, and Clark MG. Lipid infusion impairs physiologic insulin-mediated capillary recruitment and muscle glucose uptake in vivo. Diabetes 51: 1138 –1145, 2002. 53. Coe NR, Smith AJ, Frohnert BI, Watkins PA, and Bernlohr DA. The fatty acid transport protein (FATP1) is a very long chain acyl-CoA synthetase. J Biol Chem 274: 36300 –36304, 1999. 54. Cooper ME. Importance of advanced glycation end products in diabetesassociated cardiovascular, and renal disease. Am J Hypertens 17: 31S– 38S, 2004. 55. Coort SL, Hasselbaink DM, Koonen DP, Willems J, Coumans WA, Chabowski A, van der Vusse GJ, Bonen A, Glatz JF, and Luiken JJ. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes 53: 1655–1663, 2004. 56. Coort SL, Luiken JJ, van der Vusse GJ, Bonen A, and Glatz JF. Increased FAT (fatty acid translocase)/CD36-mediated long-chain fatty acid uptake in cardiac myocytes from obese Zucker rats. Biochem Soc Trans 32: 83– 85, 2004. 57. Depre C, Veitch K, and Hue L. Role of fructose 2,6-bisphosphate in the control of glycolysis. Stimulation of glycogen synthesis by lactate in the isolated working rat heart. Acta Cardiol 48: 147–164, 1993. 58. Deprez J, Vertommen D, Alessi DR, Hue L, and Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B. and other protein kinases of the insulin signaling cascades. J Biol Chem 272: 17269 –17275, 1997. 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 17. Barger PM and Kelly DP. PPARsignaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10: 238 –245, 2000. 18. Barouch LA, Berkowitz DE, Harrison RW, O’Donnell CP, and Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 108: 754 –759, 2003. 19. Barouch LA, Gao D, Chen L, Miller KL, Xu W, Phan AC, Kittleson MM, Minhas KM, Berkowitz DE, Wei C, and Hare JM. Cardiac myocyte apoptosis is associated with increased DNA damage and decreased survival in murine models of obesity. Circ Res 98: 119 –124, 2006. 20. Barr RL and Lopaschuk GD. Methodology for measuring in vitro/ex vivo cardiac energy metabolism. J Pharmacol Toxicol Methods 43: 141–152, 2000. 21. Belke DD, Larsen TS, Gibbs EM, and Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 279: E1104 –E1113, 2000. 22. Belke DD, Swanson EA, and Dillmann WH. Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53: 3201–3208, 2004. 23. Bell DS. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 18: 708 –714, 1995. 24. Bertoni AG, Tsai A, Kasper EK, and Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 26: 2791–2795, 2003. 25. Bertrand L, Alessi DR, Deprez J, Deak M, Viaene E, Rider MH, and Hue L. Heart 6-phosphofructo-2-kinase activation by insulin results from Ser-466 and Ser-483 phosphorylation and requires 3-phosphoinositidedependent kinase-1, but not protein kinase B. J Biol Chem 274: 30927– 30933, 1999. 26. Bidasee KR, Nallani K, Yu Y, Cocklin RR, Zhang Y, Wang M, Dincer UD, and Besch HR Jr. Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes 52: 1825–1836, 2003. 27. Bidasee KR, Zhang Y, Shao CH, Wang M, Patel KP, Dincer UD, and Besch HR Jr. Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2⫹-ATPase. Diabetes 53: 463– 473, 2004. 28. Boudina S, Sena S, O’Neill BT, Tathireddy P, Young ME, and Abel ED. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112: 2686 –2695, 2005. 29. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, and Popov KM. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 329: 191–196, 1998. 30. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, and Abel ED. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 146: 5341–5349, 2005. 31. Burkhoff D, Weiss RG, Schulman SP, Kalil-Filho R, Wannenburg T, and Gerstenblith G. Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. Am J Physiol Heart Circ Physiol 261: H741–H750, 1991. 32. Cai L, Li W, Wang G, Guo L, Jiang Y, and Kang YJ. Hyperglycemiainduced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51: 1938 –1948, 2002. 33. Camps L, Reina M, Llobera M, Vilaro S, and Olivecrona T. Lipoprotein lipase: cellular origin and functional distribution. Am J Physiol Cell Physiol 258: C673–C681, 1990. 34. Camps M, Castello A, Munoz P, Monfar M, Testar X, Palacin M, and Zorzano A. Effect of diabetes and fasting on GLUT-4 (muscle/fat) glucose-transporter expression in insulin-sensitive tissues Heterogeneous response in heart, red and white muscle. Biochem J 282: 765–772, 1992. 35. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, and Burrell LMA. breaker of advanced glycation end products attenuates diabetesinduced myocardial structural changes. Circ Res 92: 785–792, 2003. 36. Carley AN, Semeniuk LM, Shimoni Y, Aasum E, Larsen TS, Berger JP, and Severson DL. Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am J Physiol Endocrinol Metab 286: E449 –E455, 2004. Invited Review ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES AJP-Heart Circ Physiol • VOL 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. metabolism in the normal and diseased heart. J Mol Cell Cardiol 34: 1249 –1257, 2002. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, and Kelly DP. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109: 121–130, 2002. Forman BM, Chen J, and Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94: 4312– 4317, 1997. Francis GS. Diabetic cardiomyopathy: fact or fiction? Heart 85: 247– 248, 2001. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, and Anversa P. Myocardial cell death in human diabetes. Circ Res 87: 1123–1132, 2000. Galvez AS, Ulloa JA, Chiong M, Criollo A, Eisner V, Barros LF, and Lavandero S. Aldose reductase induced by hyperosmotic stress mediates cardiomyocyte apoptosis: differential effects of sorbitol and mannitol. J Biol Chem 278: 38484 –38494, 2003. Gargiulo CE, Stuhlsatz-Krouper SM, and Schaffer JE. Localization of adipocyte long-chain fatty acyl-CoA synthetase at the plasma membrane. J Lipid Res 40: 881– 892, 1999. Garland PB, Randle PJ, and Newsholme EA. Citrate as an intermediary in the inhibition of phosphofructokinase in rat heart muscle by fatty acids, ketone bodies, pyruvate, diabetes, and starvation. Nature 200: 169 –170, 1963. Gertz EW, Wisneski JA, Stanley WC, and Neese RA. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J Clin Invest 82: 2017–2025, 1988. Ghafourifar P, Klein SD, Schucht O, Schenk U, Pruschy M, Rocha S, and Richter C. Ceramide induces cytochrome c release from isolated mitochondria. Importance of mitochondrial redox state. J Biol Chem 274: 6080 – 6084, 1999. Ghosh S, An D, Pulinilkunnil T, Qi D, Lau HC, Abrahani A, Innis SM, and Rodrigues B. Role of dietary fatty acids and acute hyperglycemia in modulating cardiac cell death. Nutrition 20: 916 –923, 2004. Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, and van Bilsen M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92: 518 –524, 2003. Golfman LS, Takeda N, and Dhalla NS. Cardiac membrane Ca(2⫹)transport in alloxan-induced diabetes in rats. Diabetes Res Clin Pract 31, Suppl: S73–S77, 1996. Golfman LS, Wilson CR, Sharma S, Burgmaier M, Young ME, Guthrie PH, Van Arsdall M, Adrogue JV, Brown KK, and Taegtmeyer H. Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats. Am J Physiol Endocrinol Metab 289: E328 –E336, 2005. Graham BH, Waymire KG, Cottrell B, Trounce IA, MacGregor GR, and Wallace DCA. Mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 16: 226 –234, 1997. Greer JJ, Ware DP, and Lefer DJ. Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol 290: H146 –H153, 2006. Grundleger ML and Thenen SW. Decreased insulin binding, glucose transport, and glucose metabolism in soleus muscle of rats fed a high fat diet. Diabetes 31: 232–237, 1982. Gudz TI, Tserng KY, and Hoppel CL. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J Biol Chem 272: 24154 –24158, 1997. Hardie DG. Minireview: the AMPactivated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144: 5179 –5183, 2003. Hardie DG and Carling D. The AMPactivated protein kinase–fuel gauge of the mammalian cell? Eur J Biochem 246: 259 –273, 1997. Hasselbaink DM, Glatz JF, Luiken JJ, Roemen TH, and Van der Vusse GJ. Ketone bodies disturb fatty acid handling in isolated cardiomyocytes derived from control and diabetic rats. Biochem J 371: 753– 760, 2003. Hattori Y, Matsuda N, Kimura J, Ishitani T, Tamada A, Gando S, Kemmotsu O, and Kanno M. Diminished function and expression of 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 59. Derave W, Hansen BF, Lund S, Kristiansen S, and Richter EA. Muscle glycogen content affects insulin-stimulated glucose transport and protein kinase B activity. Am J Physiol Endocrinol Metab 279: E947– E955, 2000. 60. Di Filippo C, Marfella R, Cuzzocrea S, Piegari E, Petronella P, Giugliano D, Rossi F, and D’Amico M. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes 54: 803– 810, 2005. 61. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de Roos A, and Radder JK. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42: 328 –335, 2003. 62. Doria A, Nosadini R, Avogaro A, Fioretto P, and Crepaldi G. Myocardial metabolism in type 1 diabetic patients without coronary artery disease. Diabet Med 8: S104 –S107, 1991. 63. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, and Muscat GE. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17: 2477–2493, 2003. 64. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, and Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112: 1049 –1057, 2003. 65. Dyck JR, Barr AJ, Barr RL, Kolattukudy PE, and Lopaschuk GD. Characterization of cardiac malonyl-CoA decarboxylase and its putative role in regulating fatty acid oxidation. Am J Physiol Heart Circ Physiol 275: H2122–H2129, 1998. 66. Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G, Nadzan AM, and Lopaschuk GD. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94: e78 – e84, 2004. 67. Dyntar D, Eppenberger-Eberhardt M, Maedler K, Pruschy M, Eppenberger HM, Spinas GA, and Donath MY. Glucose and palmitic acid induce degeneration of myofibrils and modulate apoptosis in rat adult cardiomyocytes. Diabetes 50: 2105–2113, 2001. 68. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320: 1060 –1068, 1989. 69. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, Pieper A, Wang ZQ, Dawson TM, Snyder SH, and Dawson VL. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 3: 1089 –1095, 1997. 70. Enerback S and Gimble JM. Lipoprotein lipase gene expression: physiological regulators at the transcriptional and post-transcriptional level. Biochim Biophys Acta 1169: 107–125, 1993. 71. Entman ML, Bornet EP, Van Winkle WB, Goldstein MA, and Schwartz A. Association of glycogenolysis with cardiac sarcoplasmic reticulum: I. Effect of glycogen depletion, deoxycholate solubilization and cardiac ischemia: evidence for a phorphorylase kinase membrane complex. J Mol Cell Cardiol 9: 515–528, 1977. 72. Exil VJ, Roberts RL, Sims H, McLaughlin JE, Malkin RA, Gardner CD, Ni G, Rottman JN, and Strauss AW. Very-long-chain acylcoenzyme a dehydrogenase deficiency in mice. Circ Res 93: 448 – 455, 2003. 73. Fang ZY, Prins JB, and Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25: 543–567, 2004. 74. Fein FS. Diabetic cardiomyopathy. Diabetes Care 13: 1169 –1179, 1990. 75. Feuvray D and Lopaschuk GD. Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res 34: 113–120, 1997. 76. Finck BN. The role of the peroxisome proliferator-activated receptor alpha pathway in pathological remodeling of the diabetic heart. Curr Opin Clin Nutr Metab Care 7: 391–396, 2004. 77. Finck BN, Han X, Courtois M, Aimond F, Nerbonne JM, Kovacs A, Gross RW, and Kelly DPA. Critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 100: 1226 –1231, 2003. 78. Finck BN and Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy H1501 Invited Review H1502 100. 101. 102. 103. 104. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. the cardiac Na⫹-Ca2⫹ exchanger in diabetic rats: implication in Ca2⫹ overload. J Physiol 527: 85–94, 2000. Hauton D, Bennett MJ, and Evans RD. Utilisation of triacylglycerol and non-esterified fatty acid by the working rat heart: myocardial lipid substrate preference. Biochim Biophys Acta 1533: 99 –109, 2001. Hickson-Bick DL, Buja ML, and McMillin JB. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J Mol Cell Cardiol 32: 511–519, 2000. Hidaka S, Kakuma T, Yoshimatsu H, Sakino H, Fukuchi S, and Sakata T. Streptozotocin treatment upregulates uncoupling protein 3 expression in the rat heart. Diabetes 48: 430 – 435, 1999. Higuchi M, Miyagi K, Nakasone J, and Sakanashi M. Role of high glycogen in underperfused diabetic rat hearts with added norepinephrine. J Cardiovasc Pharmacol 26: 899 –907, 1995. Holness MJ and Sugden MC. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans 31: 1143–1151, 2003. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, Lavoinne A, Hue L, Proud C, and Rider M. Activation of AMPactivated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12: 1419 –1423, 2002. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, and Larsen TS. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 55: 466 – 473, 2006. Huang B, Wu P, Popov KM, and Harris RA. Starvation and diabetes reduce the amount of pyruvate dehydrogenase phosphatase in rat heart and kidney. Diabetes 52: 1371–1376, 2003. Hudson ER, Pan DA, James J, Lucocq JM, Hawley SA, Green KA, Baba O, Terashima T, and Hardie DG. A novel domain in AMPactivated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr Biol 13: 861– 866, 2003. Hue L, Beauloye C, Marsin AS, Bertrand L, Horman S, and Rider MH. Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways. J Mol Cell Cardiol 34: 1091–1097, 2002. Hue L and Rider MH. Role of fructose 2,6-bisphosphate in the control of glycolysis in mammalian tissues. Biochem J 245: 313–324, 1987. Huss JM and Kelly DP. Nuclear receptor signaling and cardiac energetics. Circ Res 95: 568 –578, 2004. Huss JM and Kelly DP. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest 115: 547–555, 2005. Ibrahimi A, Bonen A, Blinn WD, Hajri T, Li X, Zhong K, Cameron R, and Abumrad NA. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem 274: 26761–26766, 1999. Itani SI, Ruderman NB, Schmieder F, and Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C., and IkappaB-alpha. Diabetes 51: 2005– 2011, 2002. Itani SI, Zhou Q, Pories WJ, MacDonald KG, and Dohm GL. Involvement of protein kinase C in human skeletal muscle insulin resistance and obesity. Diabetes 49: 1353–1358, 2000. Iwasaki T, Takahashi S, Takahashi M, Zenimaru Y, Kujiraoka T, Ishihara M, Nagano M, Suzuki J, Miyamori I, Naiki H, Sakai J, Fujino T, Miller NE, Yamamoto TT, and Hattori H. Deficiency of the very low-density lipoprotein (VLDL) receptors in streptozotocin-induced diabetic rats: insulin dependency of the VLDL receptor. Endocrinology 146: 3286 –3294, 2005. Jagasia D and McNulty PH. Diabetes mellitus and heart failure. Congest Heart Fail 9: 133–139; quiz 140 –131, 2003. Jagasia D, Whiting JM, Concato J, Pfau S, and McNulty PH. Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 103: 1734 – 1739, 2001. Jeffrey FM, Diczku V, Sherry AD, and Malloy CR. Substrate selection in the isolated working rat heart: effects of reperfusion, afterload, and concentration. Basic Res Cardiol 90: 388 –396, 1995. Jensen J, Aslesen R, Ivy JL, and Brors O. Role of glycogen concentration and epinephrine on glucose uptake in rat epitrochlearis muscle. Am J Physiol Endocrinol Metab 272: E649 –E655, 1997. Jensen J, Jebens E, Brennesvik EO, Ruzzin J, Soos MA, Engebretsen EM, O’Rahilly S, and Whitehead JP. Muscle glycogen inharmoniously AJP-Heart Circ Physiol • VOL 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. regulates glycogen synthase activity, glucose uptake, and proximal insulin signaling. Am J Physiol Endocrinol Metab 290: E154 –E162, 2006. Jensen J, Ruzzin J, Jebens E, Brennesvik EO, and Knardahl S. Improved insulin-stimulated glucose uptake and glycogen synthase activation in rat skeletal muscles after adrenaline infusion: role of glycogen content and PKB phosphorylation. Acta Physiol Scand 184: 121–130, 2005. Joffe II, Travers KE, Perreault-Micale CL, Hampton T, Katz SE, Morgan JP, and Douglas PS. Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with doppler echocardiography and contribution of the nitric oxide pathway. J Am Coll Cardiol 34: 2111–2119, 1999. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, Limana F, Nadal-Ginard B, Leri A, and Anversa P. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 50: 1414 –1424, 2001. Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF, Schmidt AM, and Ramasamy R. Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann NY Acad Sci 1043: 702–709, 2005. Kashihara H, Shi ZQ, Yu JZ, McNeill JH, and Tibbits GF. Effects of diabetes and hypertension on myocardial Na⫹-Ca2⫹ exchange. Can J Physiol Pharmacol 78: 12–19, 2000. Khairallah M, Labarthe F, Bouchard B, Danialou G, Petrof BJ, and Des Rosiers C. Profiling substrate fluxes in the isolated working mouse heart using 13C-labeled substrates: focusing on the origin and fate of pyruvate and citrate carbons. Am J Physiol Heart Circ Physiol 286: H1461–H1470, 2004. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, and Shulman GI. Tissue-specific overexpression of lipoprotein lipase causes tissuespecific insulin resistance. Proc Natl Acad Sci USA 98: 7522–7527, 2001. Kim JK, Fillmore JJ, Sunshine MJ, Albrecht B, Higashimori T, Kim DW, Liu ZX, Soos TJ, Cline GW, O’Brien WR, Littman DR, and Shulman GI. PKCtheta knockout mice are protected from fat-induced insulin resistance. J Clin Invest 114: 823– 827, 2004. King KL, Okere IC, Sharma N, Dyck JR, Reszko AE, McElfresh TA, Kerner J, Chandler MP, Lopaschuk GD, and Stanley WC. Regulation of cardiac malonyl-CoA content and fatty acid oxidation during increased cardiac power. Am J Physiol Heart Circ Physiol 289: H1033– H1037, 2005. Koonen DP, Glatz JF, Bonen A, and Luiken JJ. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta 1736: 163–180, 2005. Kraegen EW, Sowden JA, Halstead MB, Clark PW, Rodnick KJ, Chisholm DJ, and James DE. Glucose transporters and in vivo glucose uptake in skeletal and cardiac muscle: fasting, insulin stimulation and immunoisolation studies of GLUT1 and GLUT4. Biochem J 295: 287– 293, 1993. Kudo N, Barr AJ, Barr RL, Desai S, and Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5⬘-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270: 17513–17520, 1995. Kudo N, Gillespie JG, Kung L, Witters LA, Schulz R, Clanachan AS, and Lopaschuk GD. Characterization of 5⬘AMP activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1301: 67–75, 1996. Kurtz DM, Rinaldo P, Rhead WJ, Tian L, Millington DS, Vockley J, Hamm DA, Brix AE, Lindsey JR, Pinkert CA, O’Brien WE, and Wood PA. Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci USA 95: 15592–15597, 1998. Laughlin MR, Petit WA Jr, Shulman RG and Barrett EJ. Measurement of myocardial glycogen synthesis in diabetic and fasted rats. Am J Physiol Endocrinol Metab 258: E184 –E190, 1990. Laybutt DR, Thompson AL, Cooney GJ, and Kraegen EW. Selective chronic regulation of GLUT1 and GLUT4 content by insulin, glucose, and lipid in rat cardiac muscle in vivo. Am J Physiol Heart Circ Physiol 273: H1309 –H1316, 1997. Lee GY, Kim NH, Zhao ZS, Cha BS, and Kim YS. Peroxisomalproliferator-activated receptor alpha activates transcription of the rat 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 105. ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES Invited Review ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES 139. 140. 141. 142. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. AJP-Heart Circ Physiol • VOL 159. Luiken JJ, van Nieuwenhoven FA, America G, van der Vusse GJ, and Glatz JF. Uptake and metabolism of palmitate by isolated cardiac myocytes from adult rats: involvement of sarcolemmal proteins. J Lipid Res 38: 745–758, 1997. 160. Maki M, Nuutila P, Laine H, Voipio-Pulkki LM, Haaparanta M, Solin O, and Knuuti JM. Myocardial glucose uptake in patients with NIDDM and stable coronary artery disease. Diabetes 46: 1491–1496, 1997. 161. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, Van den Berghe G, Carling D, and Hue L. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 10: 1247–1255, 2000. 162. Mazumder PK, O’Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, Boudina S, and Abel ED. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 53: 2366 –2374, 2004. 163. McClain DA and Crook ED. Hexosamines and insulin resistance. Diabetes 45: 1003–1009, 1996. 164. McDonagh PF and Hokama JY. Microvascular perfusion and transport in the diabetic heart. Microcirculation 7: 163–181, 2000. 165. Merkel M, Eckel RH, and Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43: 1997–2006, 2002. 166. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, and Heeren J. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280: 21553–21560, 2005. 167. Montanari D, Yin H, Dobrzynski E, Agata J, Yoshida H, Chao J, and Chao L. Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes 54: 1573–1580, 2005. 168. Monti LD, Landoni C, Setola E, Galluccio E, Lucotti P, Sandoli EP, Origgi A, Lucignani G, Piatti P, and Fazio F. Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in Type 2 diabetic patients. Am J Physiol Heart Circ Physiol 287: H1225–H1231, 2004. 169. Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, Winegar DA, Corton JC, Dohm GL, and Kraus WE. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice Evidence for compensatory regulation by PPAR delta. J Biol Chem 277: 26089 –26097, 2002. 170. Murray AJ, Anderson RE, Watson GC, Radda GK, and Clarke K. Uncoupling proteins in human heart. Lancet 364: 1786 –1788, 2004. 171. Murray AJ, Panagia M, Hauton D, Gibbons GF, and Clarke K. Plasma free fatty acids and peroxisome proliferator-activated receptor {alpha} in the control of myocardial uncoupling protein levels. Diabetes 54: 3496 –3502, 2005. 172. Nagao M, Parimoo B, and Tanaka K. Developmental, nutritional, and hormonal regulation of tissue-specific expression of the genes encoding various acyl-CoA dehydrogenases and alpha-subunit of electron transfer flavoprotein in rat. J Biol Chem 268: 24114 –24124, 1993. 173. Neely JR, Rovetto MJ, and Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 15: 289 –329, 1972. 174. Neitzel AS, Carley AN, and Severson DL. Chylomicron and palmitate metabolism by perfused hearts from diabetic mice. Am J Physiol Endocrinol Metab 284: E357–E365, 2003. 175. Newsholme EA and Randle PJ. Regulation of glucose uptake by muscle. 7 Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes, starvation, hypophysectomy and adrenalectomy, on the concentrations of hexose phosphates, nucleotides and inorganic phosphate in perfused rat heart. Biochem J 93: 641– 651, 1964. 176. Nicholl TA, Lopaschuk GD, and McNeill JH. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat heart. Am J Physiol Heart Circ Physiol 261: H1053–H1059, 1991. 177. Nielsen LB, Bartels ED, and Bollano E. Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice. J Biol Chem 277: 27014 –27020, 2002. 178. Niu YG, Hauton D, and Evans RD. Utilization of triacylglycerol-rich lipoproteins by the working rat heart: routes of uptake and metabolic fates. J Physiol 558: 225–237, 2004. 179. Nuutila P, Knuuti J, Ruotsalainen U, Koivisto VA, Eronen E, Teras M, Bergman J, Haaparanta M, Voipio-Pulkki LM, Viikari J, T. Rönnemaa, U. Wegelius, and H. Yki-Järvinen. Insulin resistance is 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 143. hepatic malonyl-CoA decarboxylase gene: a key regulation of malonylCoA level. Biochem J 378: 983–990, 2004. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, and Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106: 847– 856, 2000. Leone TC, Weinheimer CJ, and Kelly DPA. critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 96: 7473–7478, 1999. Levak-Frank S, Radner H, Walsh A, Stollberger R, Knipping G, Hoefler G, Sattler W, Weinstock PH, Breslow JL, and Zechner R. Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J Clin Invest 96: 976 –986, 1995. Li H, Wang J, Wilhelmsson H, Hansson A, Thoren P, Duffy J, Rustin P, and Larsson NG. Genetic modification of survival in tissue-specific knockout mice with mitochondrial cardiomyopathy. Proc Natl Acad Sci USA 97: 3467–3472, 2000. Li J, Hu X, Selvakumar P, Russell RR 3rd, Cushman SW, Holman GD, and Young LH. Role of the nitric oxide pathway in AMPKmediated glucose uptake and GLUT4 translocation in heart muscle. Am J Physiol Endocrinol Metab 287: E834 –E841, 2004. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, and Schaffer JE. Triglyceride accumulation protects against fatty acidinduced lipotoxicity. Proc Natl Acad Sci USA 100: 3077–3082, 2003. Liu Y, Thornton JD, Cohen MV, Downey JM, and Schaffer SW. Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarction. Circulation 88: 1273–1278, 1993. Lopaschuk GD. Alterations in myocardial fatty acid metabolism contribute to ischemic injury in the diabetic. Can J Cardiol 5: 315–320, 1989. Lopaschuk GD. Metabolic abnormalities in the diabetic heart. Heart Fail Rev 7: 149 –159, 2002. Lopaschuk GD and Barr RL. Measurements of fatty acid and carbohydrate metabolism in the isolated working rat heart. Mol Cell Biochem 172: 137–147, 1997. Lopaschuk GD, Belke DD, Gamble J, Itoi T, and Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213: 263–276, 1994. Lopaschuk GD, Saddik M, Barr R, Huang L, Barker CC, and Muzyka RA. Effects of high levels of fatty acids on functional recovery of ischemic hearts from diabetic rats. Am J Physiol Endocrinol Metab 263: E1046 –E1053, 1992. Lteif AA, Mather KJ, and Clark CM. Diabetes and heart disease an evidence-driven guide to risk factors management in diabetes. Cardiol Rev 11: 262–274, 2003. Luiken JJ, Arumugam Y, Bell RC, Calles-Escandon J, Tandon NN, Glatz JF, and Bonen A. Changes in fatty acid transport and transporters are related to the severity of insulin deficiency. Am J Physiol Endocrinol Metab 283: E612–E621, 2002. Luiken JJ, Arumugam Y, Dyck DJ, Bell RC, Pelsers MM, Turcotte LP, Tandon NN, Glatz JF, and Bonen A. Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem 276: 40567– 40573, 2001. Luiken JJ, Coort SL, Koonen DP, van der Horst DJ, Bonen A, Zorzano A, and Glatz JF. Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflügers Arch 448: 1–15, 2004. Luiken JJ, Coort SL, Willems J, Coumans WA, Bonen A, van der Vusse GJ, and Glatz JF. Contraction-induced fatty acid translocase/ CD36 translocation in rat cardiac myocytes is mediated through AMPactivated protein kinase signaling. Diabetes 52: 1627–1634, 2003. Luiken JJ, Koonen DP, Willems J, Zorzano A, Becker C, Fischer Y, Tandon NN, Van Der Vusse GJ, Bonen A, and Glatz JF. Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 51: 3113–3119, 2002. Luiken JJ, Schaap FG, van Nieuwenhoven FA, van der Vusse GJ, Bonen A, and Glatz JF. Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins. Lipids 34, Suppl: S169 –S175, 1999. Luiken JJ, Turcotte LP, and Bonen A. Protein-mediated palmitate uptake and expression of fatty acid transport proteins in heart giant vesicles. J Lipid Res 40: 1007–1016, 1999. H1503 Invited Review H1504 180. 181. 182. 183. 184. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. localized to skeletal but not heart muscle in type 1 diabetes. Am J Physiol Endocrinol Metab 264: E756 –E762, 1993. O’Donnell JM, Zampino M, Alpert NM, Fasano MJ, Geenen DL, and Lewandowski ED. Accelerated triacylglycerol turnover kinetics in hearts of diabetic rats include evidence for compartmented lipid storage. Am J Physiol Endocrinol Metab 290: E448 –E455, 2006. O’Looney P, Irwin D, Briscoe P, and Vahouny GV. Lipoprotein composition as a component in the lipoprotein clearance defect in experimental diabetes. J Biol Chem 260: 428 – 432, 1985. O’Looney P, Vander Maten M, and Vahouny GV. Insulin-mediated modifications of myocardial lipoprotein lipase and lipoprotein metabolism. J Biol Chem 258: 12994 –13001, 1983. Olson AL and Pessin JE. Transcriptional regulation of the human GLUT4 gene promoter in diabetic transgenic mice. J Biol Chem 270: 23491–23495, 1995. Ostrander DB, Sparagna GC, Amoscato AA, McMillin JB, and Dowhan W. Decreased cardiolipin synthesis corresponds with cytochrome c release in palmitate-induced cardiomyocyte apoptosis. J Biol Chem 276: 38061–38067, 2001. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, and Szabo C. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51: 514 –521, 2002. Panagia M, Gibbons GF, Radda GK, and Clarke K. PPARalpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol Heart Circ Physiol 288: H2677–H2683, 2005. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, and Zick YA. molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272: 29911–29918, 1997. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, and Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294: 169 –173, 2001. Pessin JE and Bell GI. Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu Rev Physiol 54: 911– 930, 1992. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T, and Gropler RJ. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109: 2191–2196, 2004. Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, and Davila-Roman VG. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 43: 1399 –1404, 2004. Picano E. Diabetic cardiomyopathy the importance of being earliest. J Am Coll Cardiol 42: 454 – 457, 2003. Pillarisetti S, Paka L, Sasaki A, Vanni-Reyes T, Yin B, Parthasarathy N, Wagner WD, and Goldberg IJ. Endothelial cell heparanase modulation of lipoprotein lipase activity. Evidence that heparan sulfate oligosaccharide is an extracellular chaperone. J Biol Chem 272: 15753– 15759, 1997. Pillutla P, Hwang YC, Augustus A, Yokoyama M, Yagyu H, Johnston TP, Kaneko M, Ramasamy R, and Goldberg IJ. Perfusion of hearts with triglyceride-rich particles reproduces the metabolic abnormalities in lipotoxic cardiomyopathy. Am J Physiol Endocrinol Metab 288: E1229 –E1235, 2005. Poirier P, Bogaty P, Garneau C, Marois L, and Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24: 5–10, 2001. Poornima IG, Parikh P, and Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98: 596 – 605, 2006. Raev DC. Left ventricular function, and specific diabetic complications in other target organs in young insulin-dependent diabetics: an echocardiographic study. Heart Vessels 9: 121–128, 1994. Ramasamy R, Oates PJ, and Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 46: 292–300, 1997. AJP-Heart Circ Physiol • VOL 199. Randle PJ, Garland PB, Hales CN, and Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785–789, 1963. 200. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, and Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289: 194 –202, 2003. 201. Richards MR, Harp JD, Ory DS, and Schaffer JE. Fatty acid transport protein 1 and long-chain acyl coenzyme A synthetase 1 interact in adipocytes. J Lipid Res 47: 665– 672, 2006. 202. Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG, and Hue L. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J 381: 561–579, 2004. 203. Rodrigues B, Cam MC, Jian K, Lim F, Sambandam N, and Shepherd G. Differential effects of streptozotocin-induced diabetes on cardiac lipoprotein lipase activity. Diabetes 46: 1346 –1353, 1997. 204. Rodrigues B, Cam MC, and McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27: 169 –179, 1995. 205. Rodrigues B, Cam MC, and McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 180: 53–57, 1998. 206. Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, and White MF. Insulin/IGF1 and TNFalpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 107: 181–189, 2001. 207. Rupp H, Elimban V, and Dhalla NS. Modification of myosin isozymes and SR Ca(2⫹)-pump ATPase of the diabetic rat heart by lipid-lowering interventions. Mol Cell Biochem 132: 69 – 80, 1994. 208. Russell LK, Finck BN, and Kelly DP. Mouse models of mitochondrial dysfunction and heart failure. J Mol Cell Cardiol 38: 81–91, 2005. 209. Russell RR 3rd, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, and Young LH. AMP activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114: 495– 503, 2004. 210. Saddik M and Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 266: 8162– 8170, 1991. 211. Saha AK, Vavvas D, Kurowski TG, Apazidis A, Witters LA, Shafrir E, and Ruderman NB. Malonyl-CoA regulation in skeletal muscle: its link to cell citrate and the glucose-fatty acid cycle. Am J Physiol Endocrinol Metab 272: E641–E648, 1997. 212. Saito F, Kawaguchi M, Izumida J, Asakura T, Maehara K, and Maruyama Y. Alteration in haemodynamics and pathological changes in the cardiovascular system during the development of Type 2 diabetes mellitus in OLETF rats. Diabetologia 46: 1161–1169, 2003. 213. Sakamoto J, Barr RL, Kavanagh KM, and Lopaschuk GD. Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart. Am J Physiol Heart Circ Physiol 278: H1196 –H1204, 2000. 214. Schaffer JE. Fatty acid transport: the roads taken. Am J Physiol Endocrinol Metab 282: E239 –E246, 2002. 215. Schaffer SW, Ballard-Croft C, Boerth S, and Allo SN. Mechanisms underlying depressed Na⫹/Ca2⫹ exchanger activity in the diabetic heart. Cardiovasc Res 34: 129 –136, 1997. 216. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham RE, Styles P, Radda GK, Neubauer S, and Clarke K. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 107: 3040 –3046, 2003. 217. Schonekess BO. Competition between lactate, and fatty acids as sources of ATP in the isolated working rat heart. J Mol Cell Cardiol 29: 2725–2733, 1997. 218. Semeniuk LM, Kryski AJ, and Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/dbhGLUT4 mice. Am J Physiol Heart Circ Physiol 283: H976 –H982, 2002. 219. Severson DL. Diabetic cardiomyopathy: recent evidence from mouse models of type 1, and type 2 diabetes. Can J Physiol Pharmacol 82: 813– 823, 2004. 220. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, and Taegtmeyer H. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18: 1692–1700, 2004. 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 185. ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES Invited Review ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES AJP-Heart Circ Physiol • VOL 244. Vikramadithyan RK, Hirata K, Yagyu H, Hu Y, Augustus A, Homma S, and Goldberg IJ. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J Pharmacol Exp Ther 313: 586 –593, 2005. 245. Vincent G, Bouchard B, Khairallah M, and Des Rosiers C. Differential modulation of citrate synthesis and release by fatty acids in perfused working rat hearts. Am J Physiol Heart Circ Physiol 286: H257–H266, 2004. 246. Virag L and Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375– 429, 2002. 247. Wakasaki H, Koya D, Schoen FJ, Jirousek MR, Ways DK, Hoit BD, Walsh RA, and King GL. Targeted overexpression of protein kinase Cbeta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 94: 9320 –9325, 1997. 248. Wall SR and Lopaschuk GD. Glucose oxidation rates in fatty acidperfused isolated working hearts from diabetic rats. Biochim Biophys Acta 1006: 97–103, 1989. 249. Wang P and Chatham JC. Onset of diabetes in Zucker diabetic fatty (ZDF) rats leads to improved recovery of function after ischemia in the isolated perfused heart. Am J Physiol Endocrinol Metab 286: E725– E736, 2004. 250. Wang P, Lloyd SG, Zeng H, Bonen A, and Chatham JC. Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 288: H2102– H2110, 2005. 251. Weiss J and Hiltbrand B. Functional compartmentation of glycolytic versus oxidative metabolism in isolated rabbit heart. J Clin Invest 75: 436 – 447, 1985. 252. Weiss JN and Lamp ST. Glycolysis preferentially inhibits ATP-sensitive K⫹ channels in isolated guinea pig cardiac myocytes. Science 238: 67– 69, 1987. 253. Wilson PW. Diabetes mellitus, and coronary heart disease. Endocrinol Metab Clin North Am 30: 857– 881, 2001. 254. Wojtaszewski JF, Jorgensen SB, Hellsten Y, Hardie DG, and Richter EA. Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes 51: 284 –292, 2002. 255. Wojtaszewski JF, MacDonald C, Nielsen JN, Hellsten Y, Hardie DG, Kemp BE, Kiens B, and Richter EA. Regulation of 5⬘AMPactivated EA protein kinase activity and substrate utilization in exercising human skeletal muscle. Am J Physiol Endocrinol Metab 284: E813–E822, 2003. 256. Wold LE and Ren J. Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 map kinase-dependent oxidative stress mechanism. Biochem Biophys Res Commun 318: 1066 – 1071, 2004. 257. Wu P, Inskeep K, Bowker-Kinley MM, Popov KM, and Harris RA. Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. Diabetes 48: 1593– 1599, 1999. 258. Wu P, Sato J, Zhao Y, Jaskiewicz J, Popov KM, and Harris RA. Starvation and diabetes increase the amount of pyruvate dehydrogenase kinase isoenzyme 4 in rat heart. Biochem J 329: 197–201, 1998. 259. Xing Y, Musi N, Fujii N, Zou L, Luptak I, Hirshman MF, Goodyear LJ, and Tian R. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J Biol Chem 278: 28372–28377, 2003. 260. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, and Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111: 419 – 426, 2003. 261. Yang J and Holman GD. Insulin and contraction stimulate exocytosis, but increased AMP-activated protein kinase activity resulting from oxidative metabolism stress slows endocytosis of GLUT4 in cardiomyocytes. J Biol Chem 280: 4070 – 4078, 2005. 262. Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, and Epstein PN. Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 53: 1336 –1343, 2004. 263. Ye G, Metreveli NS, Ren J, and Epstein PN. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 52: 777–783, 2003. 264. Yokoyama M, Yagyu H, Hu Y, Seo T, Hirata K, Homma S, and Goldberg IJ. Apolipoprotein B production reduces lipotoxic cardiomy- 291 • OCTOBER 2006 • www.ajpheart.org Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 221. Shen X, Zheng S, Metreveli NS, and Epstein PN. Protection of Cardiac Mitochondria by Overexpression of MnSOD Reduces Diabetic Cardiomyopathy. Diabetes 55: 798 – 805, 2006. 222. Shen X, Zheng S, Thongboonkerd V, Xu M, Pierce WM Jr. Klein JB and Epstein PN Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. Am J Physiol Endocrinol Metab 287: E896 –E905, 2004. 223. Shipp JC and Murthy VK. The heart and diabetes. Vascular and metabolic aspects. Adv Myocardiol 2: 81– 84, 1980. 224. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, and Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Diabetes 51: 1110 –1117, 2002. 225. Sowers JR, Epstein M, and Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37: 1053–1059, 2001. 226. Stamler J, Vaccaro O, Neaton JD, and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434 – 444, 1993. 227. Stanley WC, Lopaschuk GD, and McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34: 25–33, 1997. 228. Stanley WC, Recchia FA, and Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093–1129, 2005. 229. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, Turi ZG, Strauss HW, Willerson JT, Robertson T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis The MILIS Study Group. J Am Coll Cardiol 14: 49 –57, 1989. 230. Stremmel W. Fatty acid uptake by isolated rat heart myocytes represents a carrier-mediated transport process. J Clin Invest 81: 844 – 852, 1988. 231. Struthers AD and Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359: 1430 –1432, 2002. 232. Suarez J, Belke DD, Gloss B, Dieterle T, McDonough PM, Kim YK, Brunton LL, and Dillmann WH. In vivo adenoviral transfer of sorcin reverses cardiac contractile abnormalities of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 286: H68 –H75, 2004. 233. Taegtmeyer H, Hems R, and Krebs HA. Utilization of energy-providing substrates in the isolated working rat heart. Biochem J 186: 701–711, 1980. 234. Taegtmeyer H, McNulty P, and Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 105: 1727–1733, 2002. 235. Tahiliani AG and McNeill JH. Diabetes-induced abnormalities in the myocardium. Life Sci 38: 959 –974, 1986. 236. Tani M and Neely JR. Hearts from diabetic rats are more resistant to in vitro ischemia: possible role of altered Ca2⫹ metabolism. Circ Res 62: 931–940, 1988. 237. Teusink B, Voshol PJ, Dahlmans VE, Rensen PC, Pijl H, Romijn JA, and Havekes LM. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 52: 614 – 620, 2003. 238. Tontonoz P, Hu E, and Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79: 1147–1156, 1994. 239. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, and Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca(2⫹)ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51: 1166 –1171, 2002. 240. Unger RH. Lipotoxic diseases. Annu Rev Med 53: 319 –336, 2002. 241. Unger RH and Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 1585: 202–212, 2002. 242. Utriainen T, Takala T, Luotolahti M, Ronnemaa T, Laine H, Ruotsalainen U, Haaparanta M, Nuutila P, and Yki-Jarvinen H. Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia 41: 555–559, 1998. 243. Vetter R, Rehfeld U, Reissfelder C, Weiss W, Wagner KD, Gunther J, Hammes A, Tschope C, Dillmann W, and Paul M. Transgenic overexpression of the sarcoplasmic reticulum Ca2⫹ATPase improves reticular Ca2⫹ handling in normal and diabetic rat hearts. FASEB J 16: 1657–1659, 2002. H1505 Invited Review H1506 265. 266. 267. 268. ABNORMAL REGULATION OF CARDIAC SUBSTRATE METABOLISM IN DIABETES opathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem 279: 4204 – 4211, 2004. Young ME, Goodwin GW, Ying J, Guthrie P, Wilson CR, Laws FA, and Taegtmeyer H. Regulation of cardiac and skeletal muscle malonylCoA decarboxylase by fatty acids. Am J Physiol Endocrinol Metab 280: E471–E479, 2001. Young ME, Guthrie PH, Razeghi P, Leighton B, Abbasi S, Patil S, Youker KA, and Taegtmeyer H. Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes 51: 2587–2595, 2002. Young ME, McNulty P, and Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. Circulation 105: 1861–1870, 2002. Young ME, Patil S, Ying J, Depre C, Ahuja HS, Shipley GL, Stepkowski SM, Davies PJ, and Taegtmeyer H. Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB J 15: 833– 845, 2001. 269. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, and Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293: 1673– 1677, 2001. 270. Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, and Jucker BM. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 54: 554 – 562, 2005. 271. Zarain-Herzberg A, Yano K, Elimban V, and Dhalla NS. Cardiac sarcoplasmic reticulum Ca(2⫹)-ATPase expression in streptozotocininduced diabetic rat heart. Biochem Biophys Res Commun 203: 113–120, 1994. 272. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, and Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97: 1784 –1789, 2000. Downloaded from http://ajpheart.physiology.org/ by 10.220.33.6 on May 5, 2017 AJP-Heart Circ Physiol • VOL 291 • OCTOBER 2006 • www.ajpheart.org